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SUMMARY 
 
Rhabdomyolysis is an acute, and frequently severe, pathological event, characterized by rapid 
necrosis and destruction of striated muscle tissue. It is clinically characterized by muscle pain, 
weakness and emission of dark urine. The mechanisms that lead to rhabdomyolysis are various 
and different, and share common alterations such as dysfunction of the pumps Na + / K + and Ca2 
+ ATPase, and rupture of the sarcolemma, which in turn determine calcium homeostasis 
alterations, mitochondrial dysfunction, proteases activation, reduced availability of ATP and, 
overall, cell apoptosis and rhabdomyolysis. Several causes can initiate this vicious circle, both 
acquired and genetic. The acquired causes include the crush syndrome, numerous toxic, 
disendocrine diseases, but also intense exercise in favouring conditions (deconditioning, fasting, 
heat, etc.). Among the genetic causes we must include disorders of glucose metabolism (glycogen 
storage disease type V, VII, etc.), lipid metabolism (CPT2, VLCAD, etc.), mitochondrial diseases, 
some muscular dystrophies, diseases related to the metabolism of calcium (RYR1) and many 
others. 
When facing an episode of rhabdomyolysis, the identification of the etiological cause can be 
extremely complex, long, and costly. Nevertheless, the correct identification of the underlying 
cause is of utmost importance for the correct information regarding prognosis (risk of recurrence) 
and for the family genetic counselling. The diagnostic tools currently in use are: profile of 
acylcarnitines (for the diagnosis of lipid myopathy); grip test (curve of lactate after forearm strain); 
neurophysiological tests (ENG and needle EMG); muscle biopsy with biochemical assays and 
analysis of muscle protein; and molecular analysis of candidate genes. 
Despite the application of an extended diagnostic work up, however, frequently it is not easy to 
distinguish if the rhabdomyolysis episode is due to a genetic disorder or whether it is the result of 
an abnormal effort, of an infectious episode or effect of a toxic. In recent years, the evolution of 
molecular techniques allowed to develop methods for the analysis of exomes ("whole exome 
sequencing") or of several genes involved in specific diseases ("gene panels"). These techniques 
allowed us to increase the detection rate, reducing time and cost analysis, and have identified new 
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genes associated with myopathies. At the same time, it eased the identification of genetic variants 
whose pathogenicity is still doubtful and it is still far from identifying all molecular mechanisms 
underlying rhabdomyolysis. A careful analysis of the clinical picture of the patient, the correct 
choice of diagnostic tools and their careful evaluation is mandatory for the proper selection and 
interpretation of molecular investigations. 
The main objective of this study is, therefore, the evaluation of the diagnostic process of cases of 
rhabdomyolysis, to propose an updated, comprehensive, rational and cost effective protocol based 
on the latest information and techniques. 
The first objective of the study (aim 1) was the analysis of the clinical features and diagnostic 
procedures performed in patients with rhabdomyolysis. This retrospective study included all the 
patients referred for rhabdomyolysis to a Reference Centre for Neuromuscular Diseases (n = 208, 
2000 - 2016). We verified that, despite an extensive work up (EMG, muscle biopsy, acylcarnitines, 
biochemical and genetic analyses), the diagnosis of genetic myopathy was done only in 41 
patients (GSDV, CPT2, RYR1 and other) and of rhabdomyolysis of non-genetic origin only in 49 
("pure exertional rhabdomyolysis", toxic, infectious, etc.). In 118 patients, the cause could not be 
identified. Some diagnostic tests have shown high specificity and sensitivity for specific diseases: 
grip tests in the diagnosis of McArdle's disease and in phosphoglucomutase 1 deficit; profile of 
acylcarnitines in VLCAD and CPT2 deficiency; muscle biopsy in McArdle's disease and in some 
muscular dystrophies. Overall, however, the diagnostic tools were insufficient in guiding the 
diagnostic process to a defined etiologic diagnosis, as a molecular diagnosis was acquired only in 
20% of patients. 
The second aim of the study (aim 2) was the clinical, radiological, and molecular characterization 
of patients affected by a recently identified myopathy, the CASQ1 –related myopathy, that here we 
identified as potentially complicated by rhabdomyolysis. The disease has been identified in several 
Italian patients, all carrying the same mutation (p.Asp244Gly ) because of a founder effect. 
Screening of the biobank and subsequent genetic analysis of the gene (with "ARMS-PCR", and 
sequencing) led us to identify the common mutation in 16 patients, and a novel mutation 
(p.Gly103Asp) in another. Clinical characteristics and evolution of the disease were evaluated by 
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medical record review, ad hoc structured questionnaires, multi-disciplinary clinical evaluation 
(neurological, cardiac and pulmonary clinic), and muscle MRI. In the present study, we show that 
this disease, which was considered benign, is a slowly progressive myopathy frequently 
manifesting iperCKemia, exertional myalgias and rhabdomyolysis. We also provide information 
about the clinical features, muscle imaging and histopathology that orient towards the diagnosis of 
CASQ1-related myopathy. 
Aim 3 was to determine the clinical spectrum of limb-girdle muscular dystrophy 2E (LGMD2E), and 
to investigate the risk of rhabdomyolysis of this disease. We also investigated whether genetic or 
biochemical features can predict the phenotype of the disease.  We included 32 European patients 
(16M-16F; age 7-67) in a multicentre study, with a specific multidisciplinary clinical protocol and ad 
hoc questionnaires. Molecular analysis of SGCB gene and biochemical features of muscle 
biopsies were also reviewed.  All patients presented clinical features compatible with LGMD. We 
did not identify any episode of rhabdomyolysis. However, 75% of ambulant patients and no 
wheelchair-bound patients reported muscle pain. This suggests a membrane fragility that in certain 
cases could therefore also determine the more severe rhabdomyolysis. We also confirmed that 
cardiac involvement is frequent (63%) even before overt muscle involvement.  We finally provide 
strong evidence that severity of clinical involvement may be predicted by SGCB gene mutation and 
sarcoglycan protein expression. 
Aim 4 focused on diagnostic tools to be used in cases of rhabdomyolysis, and in particular on the 
role of EMG with provocative test: the Long Exercise Test (LET) for the diagnosis of McArdle 
disease (GSDV). We included 25 GSDV patients, 25 patients with rhabdomyolysis from other 
causes, and 14 healthy controls. All patients underwent to a complete neurophysiological protocol 
including standard ENG and EMG, repetitive stimulation, short exercise test and LET. LET in 
GSDV patients showed a marked and immediate reduction of compound action potential (CMAP) 
amplitude. This anomaly is indicative of membrane inexcitability that occurs after exertion in GSDV 
patients. We therefore demonstrated the role of the LET in the diagnosis of GSDV, to discriminate 
it from rhabdomyolysis due to other causes. LET can also be used as an outcome measure, 
because it is related to the severity of symptoms and is consistent with post-exercise symptoms 
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reported by patients. Furthermore, it is an in vivo evaluation of pathophysiological processes 
underlying the disease beyond the simple glycolytic blockade. 
Aim 5 consisted in the creation of a multi gene panel that should be studied by Next Generation 
Sequencing (NGS) in patients presenting rhabdomyolysis. This should include at least the 32 
genes involved in mechanisms that are known to be disrupted in rhabdomyolysis and in 
pathologies that are known to manifest with rhabdomyolysis, such as glycogen metabolism, lipid 
metabolism, and calcium homeostasis disorders.    
  
In conclusion, the results of this study (the diagnostic process currently in use and the identification 
of rare causes of rhabdomyolysis; the identification of CASQ1 as a new genetic cause of 
rhabdomyolysis; and the demonstration of the role of EMG with LET as a sensitive and specific 
diagnostic test in the work up of rhabdomyolysis), suggest a new diagnostic algorithm for 
rhabdomyolysis. In this algorithm, the clinical features and few first-line tests (blood tests, EMG, 
acylcarnitines, grip test) exclude the most frequent causes or the treatable ones. The subsequent 
muscle biopsy will identify certain myopathies and guide toward the use of specific genetic panels 
for metabolic myopathies, muscular dystrophies or mitochondrial diseases that should be studied 
by NGS. Any identified variation will be confirmed according to clinical and laboratory data. The 
“pure exertional rhabdomyolysis" remains a diagnosis of exclusion in most cases, and in these 
cases we cannot exclude genetic variations that affect the physiological response to exercise. The 
diagnostic algorithm that we propose will allow cost reduction and time optimization, and hopefully 
will increase the rate of etiological diagnosis of rhabdomyolysis, a serious event with major impact 
on patients' lives that, to date, remains poorly diagnosed. 
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Riassunto  
 
 
La rabdomiolisi è un evento patologico acuto e talvolta grave, caratterizzato da rapida necrosi e 
distruzione del tessuto muscolare striato alla quale corrisponde clinicamente dolore e debolezza 
muscolare ed emissione di urine scure. I meccanismi che portano alla rabdomiolisi sono vari e 
differenti ma condividono alterazioni comuni quali la disfunzione delle pompe Na+/K+ e Ca2+ 
ATPAsi, e la rottura del sarcolemma, che a loro volta determinano alterazioni dell’omeostasi del 
calcio, disfunzione mitocondriale, attivazione di proteasi, riduzione della disponibilità di ATP e, 
complessivamente, apoptosi cellulare e rabdomiolisi. Numerose cause possono dare avvio a tale 
circolo vizioso, sia acquisite che genetiche. Le cause acquisite includono la sindrome da 
schiacciamento, numerosi tossici, malattie disendocrine, ma anche e soprattutto l’esercizio fisico 
intenso specie in condizioni favorenti (decondizionamento, digiuno, calore, etc.).  Tra le cause 
genetiche si annoverano patologie del metabolismo glucidico (glicogenosi tipo V, VII, etc.) e 
lipidico (CPT2, VLCAD, etc.), malattie mitocondriali, alcune distrofie muscolari, patologie correlate 
al metabolismo del calcio (RYR1) e molte altre. 
La corretta identificazione della causa sottostante è di estrema importanza per una corretta 
informazione al paziente a fini prognostici (rischio di ricorrenza) e per il counseling genetico 
familiare. Di fronte ad un episodio di rabdomiolisi, l’iter per determinare la causa etiologica può 
essere lungo, complesso e costoso. Tra gli strumenti diagnostici attualmente in uso vi sono il 
profilo delle acilcarnitine (per la diagnosi di miopatia lipidica); il test da sforzo anaerobico per il 
lattato detto “grip test” (curva del lattato dopo sforzo dell’avambraccio); l’EMG ad ago (per 
individuare eventuali segni di miopatia);la biopsia muscolare con eventuali dosaggi biochimici e 
analisi delle proteine muscolari; ed infine l’ analisi molecolare di geni candidati.  
Nonostante l’applicazione di questo complesso work up diagnostico, non è sempre facile 
determinare se alla base di un episodio di rabdomiolisi vi sia una patologia genetica o se sia 
esclusivamente conseguenza di uno sforzo, di un episodio infettivo o dell’effetto di un tossico. 
Negli ultimi anni, l’evoluzione delle tecniche molecolari ha permesso di mettere a punto metodiche 
per l’analisi dell’esoma (“whole exome sequencing”) o per l’analisi simultanea di numerosi geni 
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coinvolti in malattie specifiche (“gene panels”). Tali tecniche hanno permesso di aumentare il 
numero delle diagnosi, riducendo i tempi e i costi dell’analisi ed hanno permesso di identificare 
nuovi geni associati a miopatie con rabdomiolisi. Contemporaneamente all’aumento della 
identificazione di geni causativi di rabdomiolisi è aumentata anche l’identificazione di varianti 
genetiche la cui patogenicità è dubbia e che pongono notevoli difficoltà nella consulenza genetica. 
Nonostante tutti questi avanzamenti diagnostico-molecolari si è ancora lontani dall’identificazione 
di tutti i meccanismi patogenetici ed al riconoscimento di tutti i geni alla base delle rabdomiolisi.  
Un’attenta analisi del quadro clinico del paziente, la corretta scelta degli strumenti 
diagnostici ed una valutazione attenta dell’esito degli stessi è necessaria per indirizzare le indagini 
molecolari. L’obiettivo principale del presente studio è stato, pertanto, definire l’iter diagnostico 
ottimale in caso di rabdomiolisi, al fine di proporne uno aggiornato, completo, razionale ed 
economico che includa le più recenti nozioni e tecniche.  
 
Il primo obiettivo dello studio (aim 1) è stato l’analisi delle caratteristiche cliniche e delle 
procedure diagnostiche eseguite in pazienti con rabdomiolisi. Lo studio retrospettivo ha incluso 
tutti i pazienti giunti per rabdomiolisi ad un Centro di Riferimento per Malattie Neuromuscolari (n = 
208, periodo 2000 – 2016). Abbiamo verificato come, malgrado l’esteso work up al quale sono stati 
sottoposti i pazienti (EMG, acilcarnitine, biopsia muscolare, indagini biochimiche e genetiche), si è 
giunti alla diagnosi di miopatie genetiche solo in 41 pazienti (∼20%) (GSDV, CPT2, RYR1 e altre) e 
di rabdomiolisi su base non-genetica solo in 49 (∼23%) (rabdomiolisi da sforzo “pura”, cause 
tossiche, infettive, etc.).  In 118 pazienti la causa non è stata identificata. Alcuni test diagnostici 
hanno dimostrato elevata specificità e sensibilità in determinate patologie: “grip test” nella diagnosi 
di Malattia di McArdle e nel deficit di fosfoglucomutasi 1; profilo delle acilcarnitine nel deficit di 
VLCAD e CPT2; biopsia muscolare nella malattia di McArdle e in alcune distrofie muscolari.  
Complessivamente gli strumenti finora in uso si sono dimostrati insufficienti nel guidare l’iter 
diagnostico verso una diagnosi eziologica definita considerando che nel 57% dei pazienti non sono 
state identificate le cause degli episodi di rabdomiolisi.  
Il secondo obiettivo dello studio (aim 2) è stata la caratterizzazione clinica, radiologica, e 
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molecolare dei pazienti affetti da una miopatia, talora associata a rabdomiolisi, che il nostro gruppo 
ha recentemente identificato, la miopatia da mutazioni nel gene CASQ1. Sulla base delle 
caratteristiche istologiche identificate nei primi pazienti descritti è stato condotto uno screening 
della nostra biobanca per l’individuazione di pazienti candidati.  Questi sono stati sottoposti ad 
analisi del gene CASQ1 con “ARMS-PCR” e sequenziamento.  In In 16 pazienti è stata identificata 
la mutazione comune p.Asp244Gly ed in un singolo paziente una mutazione mai 
descritta,p.Gly103Asp.  Lo studio degli aplotipi nei pazienti con la mutazione comune ha permesso 
di ipotizzare un effetto del portatore.  Le caratteristiche cliniche e l’evoluzione della malattia sono 
state valutate mediante revisione delle cartelle cliniche, questionari strutturati creati ad hoc, 
valutazione clinica multidisciplinare (neurologica, cardiologica e pneumologica) e RM muscolare.  
Nel presente studio dimostriamo che la miopatia CASQ1-relatasia una miopatia lentamente 
evolutiva che si manifesta frequentemente con iperCKemia, mialgie da sforzo e rabdomiolisi. 
Descriviamo anche le caratteristiche cliniche, di imaging muscolare e di istopatologia, che possono 
orientare verso la diagnosi. 
Il terzo obiettivo (aim 3) è stato lo studio, in un’ampia coorte di pazienti europei (Italia, 
Francia, Danimarca), delle caratteristiche cliniche della distrofia muscolare 2E (LGMD2E) ed in 
particolare dell’occorrenza di rabdomiolisi. Sono stati quindi raccolti dati anamnestici, mediante 
revisione delle cartelle cliniche e raccolta di questionari ad hoc, ed è stato proposto uno specifico 
protocollo di valutazione clinica, multidisciplinare. Sono stati anche valutati i fattori genetici o 
istopatologici possano essere predittivi del fenotipo Sono stati inclusi nello studio 32 pazienti (16M-
16F; età 7-67 anni). Tutti i pazienti presentavano un quadro clinico tipico per una distrofia dei 
cingoli. Non sono stati evidenziati episodi di rabdomiolisi; tuttavia il 75% dei pazienti adulti riferiva 
dolore muscolare cronico, che invece non era mai presente nei pazienti non deambulanti. Cio’ 
suggerisce la presenza di fragilità di membrana che potrebbe in talune circostanze condurre anche 
a rabdomiolisi. Nello studio è inoltre stato osservato un interessamento cardiaco in oltre la metà 
dei pazienti (63%), ed un’insufficienza respiratoria tale da richiedere ventilazione meccanica nel 
19%. È stato inoltre possibile determinare una correlazione tra genotipo, espressione proteica e 
severità di malattia.   
   
 
 
 
10 
Il quarto obiettivo dello studio (aim 4) è stato centrato sugli strumenti diagnostici utilizzabili 
in caso di rabdomiolisi, ed in particolare sul ruolo dell’EMG con test provocativi come il test di 
esercizio prolungato per la diagnosi della malattia di McArdle (GSDV).  Sono stati confrontati 25 
pazienti GSDV, 25 pazienti con rabdomiolisi da altre cause e 14 controlli sani. Tutti sono stati 
sottoposti a protocollo neurofisiologico completo con EMG ed ENG standard, stimolazione 
ripetitiva, test di esercizio breve e prolungato.  Il test di esercizio prolungato (Long Exercise Test, 
LET) ha evidenziato una netta e immediata riduzione del potenziale d’azione composto (CMAP) 
dopo esercizio nei pazienti GSDV. Tale anomalia è indicativa dell’ineccitabilità di membrana che si 
manifesta dopo sforzo in questi pazienti. Abbiamo quindi dimostrato il ruolo del LET nella diagnosi 
di GSDV, in particolare nel discriminarla dalla rabdomiolisi da altre cause. Abbiamo anche 
dimostrato come il test possa essere utilizzato come misura di outcome perché correlato alla 
gravità dei sintomi e coerente con i sintomi post-esercizio riferiti dai pazienti, e come strumento di 
valutazione in vivo dei processi fisiopatologici alla base della malattia.  I risultati del test LET nella 
GSDV suggeriscono che anche in questa malattia l’ineccitabilità di membrana secondaria al blocco 
della produzione di ATP e alla disfunzione dei canali di membrana e del reticolo giochi un ruolo 
patogenetico significativo. 
 Il quinto obiettivo dello studio (aim 5) è stata la creazione di uno specifico pannello di geni 
da studiare mediante Next Generation Sequencing (NGS) nei pazienti che presentino rabdomiolisi. 
Sono stati selezionati pertanto i geni potenzialmente coinvolti nei meccanismi alla base delle 
rabdomiolisi, ovvero quelli principalmente coinvolti nel metabolismo lipidico, glucidico e 
nell’omeostasi del calcio intracellulare.  
In conclusione, con le evidenze raccolte nel presente studio (la definizione dello stato 
dell’arte dell’iter diagnostico correntemente in uso nello studio dei pazienti con rabdomiolisi, 
l’identificazione di una causa rara di rabdomiolisi, la miopatia CASQ1-relata, e la dimostrazione del 
ruolo dell’ EMG con test di esercizio prolungato nell’identificazione dei pazienti con GSDV), 
proponiamo un nuovo algoritmo diagnostico per le rabdomiolisi. In tale algoritmo le caratteristiche 
cliniche e pochi test di primo livello (esami ematochimici, EMG, profilo delle acilcarnitine, “grip 
test”) permettono di escludere le cause più frequenti o trattabili. La biopsia muscolare, esame di 
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secondo livello, permetterà di identificare talune miopatie e guiderà il ricorso a specifici pannelli 
genetici per le miopatie metaboliche, le distrofie muscolari dei cingoli e le malattie mitocondriali. La 
rabdomiolisi da sforzo “pura” rimane una diagnosi di esclusione nella maggior parte dei casi. In 
questi casi lo studio di variazioni genetiche polimorfiche potrebbe portare all’identificazione di 
modificatori genetici della risposta all’esercizio.  L’algoritmo diagnostico proposto permetterà però 
di contenere i costi ed ottimizzare i tempi della diagnosi, e auspicabilmente aumenterà il rate di 
diagnosi etiologiche della rabdomiolisi, un evento grave e con un notevole impatto sulla vita dei 
pazienti ma che ad oggi resta scarsamente diagnosticato.  
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INTRODUCTION 
 
The word rhabdomyolysis uses the combining forms rhabdo- + myo- + -lysis, yielding a generic 
"striated muscle breakdown". Clinically, rhabdomyolysis is an acute, potentially life-threatening, 
syndrome characterised by the breakdown of skeletal muscle resulting in the subsequent release 
of intracellular contents into the circulatory system. These include enzymes such as creatine 
kinase (CK), glutamic oxalacetic transaminase, lactate dehydrogenase, aldolase, the haeme 
pigment myoglobin, electrolytes such as potassium and phosphates, and purines (Warren 2002; 
Huerta-Alardın et al, 2005; Khan et al, 2009; Zutt et al, 2014; Chavez 2016) 
 
DEFINITION  
The clinical definition of rhabdomyolysis is still debated. In fact, the normal physiological responses 
to strenuous exercise and clinically significant exertional rhabdomyolysis (ER) have considerable 
overlap in their major clinical and serological markers. The main clue in rhabdomyolysis is the 
observation of increased CK level. However, there is no agreement on which value of CK is 
significant to define a rhabdomyolysis. The most recent laboratory diagnostic guidelines and 
clinical studies (mostly proposed for internal medicine purposes, such as to evaluate statin side 
effects) define rhabdomyolysis with different CK levels. Rhabdomyolysis is usually defined when 
CK levels are 5 to 10 times the ULN (>1,000 U/L). These limits, however, have a too low 
specificity, including also physiological responses to exercise or effort, thus limiting its role in the 
diagnosis of exertional rhabdomyolysis, for example in military trainees or athletes. Other studies 
proposed CK levels of > 50 ULN (corresponding to a > 12,000 IU/L). This more stringent limit 
improves specificity, but would exclude several patients with potential subjacent muscle diseases. 
Futhermore, it is important to observe not only the peak of CK level, but also its relationship with 
rest (or inter-critical) level. In fact, CK levels very high, even greater than 15,000 U/L, can be 
observed in several muscular dystrophies (Harris et al, 2016). In such cases however these values 
are persistent (Pasternak et al, 2002; McKenney et al, 2006; Sewright et al, 2007)  
It is not possible to define rhabdomyolysis only by its clinical features. In fact, muscle pain and 
soreness after effort are very frequent among healthy subjects . On the other hand, the 
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appearence of dark-colored urines is not always present also in episodes of overt rhabdomyolyis 
with very high CK levels.  The combination of clinical and biochemical information (symptoms, CK 
level, triggers, etc.) should therefore be used to correctly identify the episodes of rhabdomyolysis. 
The severity of the event, then, should to be classified according to CK levels and complications.  
CLINICAL FEATURES OF RHABDOMYOLYSIS  
Rhabdomyolysis ranges in severity from asymptomatic elevation of CK levels in blood, to severe 
life-threatening episodes associated with very high CK levels, myoglobinuria and acute renal 
failure, multi-systemic failure. Clinically it manifests with a triad of symptoms: myalgia, weakness, 
and myoglobinuria, observed as the classically described tea-colored (or “coca-cola” or “porto”) 
urine. This rigid depiction of symptoms can be misleading as the triad is only observed in <10% of 
patients. Patients may also report tense and swollen muscles or muscle edema. Systemic 
manifestations may include tachycardia, general malaise, fever, and nausea and vomiting and as 
such are nonspecific. The clinical manifestations of acute kindey failure (AKI), disseminated 
intravascular coagulation, and multiorgan failure may subsequently appear. 
COMPLICATIONS OF RHABDOMYOLYSIS AND TREATMENT 
Major complications of rhabdomyolysis and their treatment are shown in Figure 1. 
Myoglobinuria occurs only in the context of rhabdomyolysis. Acute kidney injury (AKI) associated 
with myoglobinuria is the most serious complication of both traumatic and nontraumatic 
rhabdomyolysis, and it may be life threatening. An estimated 10%-40% of patients with 
rhabdomyolysis develop AKI, and up to 15% of all cases of ARF can be attributed to 
rhabdomyolysis (Kasaoka et al 2010). The exact mechanisms by which rhabdomyolysis impairs 
the glomerular filtration rate are unclear. Experimental evidence suggests that intrarenal 
vasoconstriction, direct and ischemic tubule injury, and tubular obstruction all play a role (Bosch et 
al, 2009).  
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Fig. 1. Complications of 
rhabdomyolysis and 
treatments (from Torres 
et al, 2015) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATHOMECHANISMS 
Although the causes of rhabdomyolysis are very diverse, the pathogenesis appears to follow a final 
common pathway, ultimately leading to myocyte destruction and release of muscle components 
into the circulation.  Irrespective of the initial insult, the final steps involve either direct myocyte 
injury or a failure of the energy supply within the muscle cells (Fig. 2).  
In the normal myocyte, several sarcolemmal pumps accurately regulate cellular electrochemical 
gradients. The intercellular sodium concentration is normally maintained at 10 mEq/l by a sodium-
potassium adenosine triphosphatase (Na/K-ATPase) pump located in the sarcolemma. The Na/K-
ATPase pump actively transports sodium from the interior of the cell to the exterior. As a result, the 
interior of the cell is more negatively charged than the exterior because positive charges are 
transported across the membrane. The gradient pulls sodium to the interior of the cell in exchange 
for calcium by a separate ion exchange channel. Moreover, low intracellular calcium levels are also 
maintained by an active calcium exchanger (Ca2+ ATPase pump) that promotes calcium entry into 
the sarcoplasmic reticulum and mitochondria. The above processes depend on ATP as a source of 
energy.  When muscle injury or ATP depletion occurs, the result is an excessive intracellular influx 
of Na+ and Ca2+. ATP depletion results in Na/K-ATPase and Ca2+ ATPase pump dysfunction, the 
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end result of which is an increased cellular permeability to sodium ions. Accumulation of sodium in 
the cytoplasm leads to an increase in intracellular calcium concentration, that leads to a sustained 
myofibrillar contraction that further depletes ATP. Futhermore, Ca2+ concentration determines the 
activation of intracellular proteolytic enzymes that degrade the muscle cell. Futhermore, the 
increase in intracellular Na+ draws water into the cell and disrupts the integrity of the intracellular 
space (Guis et al, 2005; Zutt et al, 2014; Torres et al, 2015; Olpin et al, 2015).  
 
Fig. 2. Mechanisms of rhabdomyolysis (From Kahn et al, 2009). 
 
 
 
As the myocyte degenerates, large quantities of potassium, aldolase,phosphate, myoglobin, CK, 
lactate dehydrogenase, aspartate transaminase and urate leak into the circulation. Under 
physiological conditions, the plasma concentration of myoglobin is very low (0 to 0.003 mg per dl). 
If more than 100 g of skeletal muscle is damaged, the circulating myoglobin levels exceed the 
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protein-binding capacity of the plasma and can precipitate in the glomerular filtrate. Excess 
myoglobin may thus cause renal tubular obstruction, direct nephrotoxicity, and acute renal failure.  
 
 
CAUSES OF RHABDOMYOLYSIS 
 
Several genetic and non-genetic (or acquired) causes of rhabdomyolysis have been identified (Fig. 
3). It is to note that in individual cases both genetic and environmental factors may combine to 
trigger a rhabdomyolysis event. 
 
 
 
 
Fig. 3. Acquired and genetic conditions associated with Rhabdomyolysis..  
(From Scalco et al, 2015) 
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Non-genetic (acquired) causes  
The numerous non-genetic causes that have been demonstrated as cause of rhabdomyolysis are 
extensively shown in Table I. “Crush syndrome” is the term usually used to describe muscle 
destruction after direct trauma, injury, or compression.  Exercise/Exertion: the occurrence of 
rhabdomyolysis has been especially studied in military personnel enrolled in basic military training; 
the incidence of exertional rhabdomyolysis was estimated 22.2 cases per 100,000 recruits per year 
(Alpers et al, 2010). Exertional rhabdomyolysis is usually characterized by low incidence in an 
active population, few complications relative to other causes in the acute setting, and infrequent 
long-term recurrence after return to prior levels of physical activity (Huynh et al, 2016; Lozowska et 
al, 2015). It is to note that serum CK levels will naturally rise after strenuous exercise in almost all 
normal humans, potentially up to 10 times the higher limit of normal, thus the limit between normal 
response to exercise and overt rhabdomyolysis is blurred (Kobayashi  et al, 2005; Kenney et al, 
2012). Toxic: the use of several drugs can determine rhabdomyolysis, via all the previously 
described pathomechanisms. The complete list is shown in Table I. Due to their large use in the 
global population, statins are the most frequently involved as cause of rhabdomyolysis. However, 
even if signs of myopathic toxicity are frequently reported (myalgias is observed in up to 10% of 
statin users), episodes of overt rhabdomyolysis remain a rare side effect (Joy and Hegele, 2009; 
Iwere et al, 2015; Collins et al, 2016) . Infections: Rhabdomyolysis has been described in all types 
of infections, ranging from localized muscle infections with erythema (bacterial pyomyositis) to 
patients with  sepsis and no direct muscle infection.  Proposed mechanisms for the development of 
rhabdomyolysis include tissue hypoxia secondary to sepsis or dehydration, toxin release, 
associated fever, direct bacterial invasion of muscle, or rigors/tremors. Classically, Legionella 
bacteria have been associated with bacterial rhabdomyolysis. Viral infections have also been 
implicated in rhabdomyolysis development, most commonly influenza A and B viruses (Tseytlin et 
al, 2016). 
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Table I. Non genetic causes of rhabdomyolysis (modified from Warren et al, 2002) 
Exertion)
Exercise;)status)epilepticus;)delirium;)psychosis;)electric)shock,)electroconvulsive)therapy;)prolonged
cardiopulmonary)resuscitation)and)cardioversion;)status)asthmaticus;)tetanus;)prolonged)myoclonus,)
dystonia)or)chorea;)conga)drumming;)keyboard)operation;)raver’s)hematuria
Crush
External)weight;)prolonged)immobility)(including)coma,)Parkinson’s)disease);)exaggerated)lithotomy)position)and)
other)surgical)positions;)“pseudo@crush”)syndrome)(torture)victims,)child)abuse);)pneumatic)antishock)garment
Ischemia
Arterial)occlusion;)compartment)syndrome;)cardiopulmonary)bypass;)vena)cava)ligation;
sickle)cell)disease;)air)embolism;)atrial)myxoma;)diabetes)mellitus;)increased)capillary)permeability)syndrome
Metabolic)
Hypokalemia;)diabetic)ketoacidosis;)nonketotic)hyperglycemic/hyperosmolar)states;)hyper/hyponatremia;)
hypophosphatemia;hypothyroidism;)near)drowning;)renal)tubular)acidosis;)pancreatitis
Extremes)of)body)temperature)
Fever;)burns;)hypothermia)(exposure,)hypothyroidism)
Drugs)and)toxins
Metabolic
statins;)anticholinergics;)antidepressants)(all)classes);)antihistamines)(diphenhydramine,)doxylamine);)arsenic;)
azathioprine;)barbiturates;benzodiazepines;)bezafibrate;)carbon)monoxide;)clofibrate;)cytotoxics;)ethanol;)
ethylene)glycol;)fenfluramine;)gemfibrozil;)glutethamide;)interferon@);)methanol;)naltrexone;)opiates;)propofol;)
oxprenolol;)labetolol;)paracetamol;)podophyllin;)zidovudine;)streptokinase;)alteplase
Hypokalemia
Amphotericin;)carbenoxolone;)glycirrhizate)(licorice);)itraconazole;)laxative)abuse
thiazides)and)other)kaliuretics
Ischemia
)@Aminocaproic)acid;)cocaine;)vasopressin
Autoimmune
Cyclosporin;)levodopa;)nonsteroidals;)penicillamine;)phenylbutazone;)phenytoin;)trimethoprim–sulfamethoxazole
Membrane6effect
Carbon)tetrachloride;)cimetidine;)colchicine;)didanosine;)hydrocarbons;)herbicides;)iron)dextran;)metal)fumes;
quinidine;)solvents;)detergents;)succinylcholine;)toluene;)vecuronium,)pancuronium;
snake/spider/hornet/bee/fugu/parrotfish)venoms
Agitation6
Hemlock)(?)quail)eaters);)ketamine;)lithium;)LSD;)mercuric)chloride;)phencyclidine;)salicylates;)terbutaline
Neuroleptic6malignant6syndrome
Butyrophenones;)levodopa)and)dopamine)agonist)withdrawal;)lithium;)pimozide;)promethazine;)thioxanthenes
Serotonergic)syndrome
Amphetamines;)Ecstasy;)lithium;)monoamine)oxidase)inhibitors;)nefazodone;)pethidine;)
tricyclic)antidepressants;)tryptophan;)venlafaxine
Mechanism6uncertain
Amiodarone;)blowpipe)dart)poisoning;)chromium)picolinate;)isoniazid;)kidney)beans;)lamotrigine;)nicotinic)acid;
peanut)oil;)pentamidine;)valproate
Infections
Viral
Adenovirus;)cytomegalovirus)(CMV);)Coxsackie;)Enterovirus;)Epstein–Barr)(EBV);)human)immunodeficiency)virus)
(HIV);)herpes)simplex)(HSV);)influenza)A)and)B;)measles;)Varicella)zoster
Bacterial
Bacillus)spp.;)Borrelia)burgdorferi;)Brucella;)Campylobacter;)Clostridia;)Coxiella;)Escherichia)coli;)Enterobacter;)
H.)influenzae;)Legionella;)Leptospira;)Listeria;)Salmonella;)Shigella;)Staphylococcus;)Streptococcus;)tetanus;)typhoid;)
Other
Aspergillus;)Candida;)Mycoplasma;)Plasmodium;)Toxoplasma;)Trichinella
Inflammatory)and)autoimmune)muscle)disease
Polymyositis;)dermatomyositis;)vasculitides;)carcinoma)(paraneoplastic)necrotizing)myopathy)
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Genetic Causes  
Genetic causes of myopathic rhabdomyolysis include metabolic myopathies (glycogen or lipid 
metabolism impairment; mitochondrial disease), calcium-related myopathies (RYR1 mutation and 
other triadopathies), muscular dystrophies and other diseases. 
- Metabolic myopathies 
Metaoblic myopathies are caused by enzymatic defects of the biochemical pathways that produce 
ATP. It can result either from defects in substrate utilization (disorders of glycogen and lipid 
metabolism) or mitochondrial respiratory chain (mitochondrial myopathies). Typically they are 
divided into two main clinical presentations: dynamic symptoms (exercise intolerance / myalgia / 
cramps, with recurrent rhabdomyolysis) or static symptoms (progressive muscle weakness 
mimicking muscular dystrophies).  Although this division based on clinical presentation is very 
helpful, it should be known that patients with dynamic symptoms may also present with some 
degree of muscle wasting occurring during the course of the disease, and conversely patients with 
permanent muscle weakness may also have exercise-related symptoms of fatigue and pain. The 
present work will be focused focused on those pathologies potentially manifesting with the 
“dynamic symptoms”, including rhabdomyolysis. 
A) Muscle glycogenosis 
Deficiencies of virtually all enzymes that intervene in the synthesis or degradation of glycogen may 
cause glycogen storage disease (GSD) due to aberrant storage or utilization of glycogen. These 
disorders are inherited as autosomal recessive traits, with the exception of phosphoglycerate 
kinase and phosphorylase b kinase deficiencies, which are X-linked recessive (DiMauro et al., 
2004). Usually patients with glycogenosis and exercise intolerance develop symptoms early in 
exercise, but exercise intensity at which symptoms occur can vary according to the residual activity 
of the affected enzyme. 
Glycogen Storage Disease Type V (GSDV) or McArdle disease. McArdle disease is the most 
frequent “dynamic” metabolic myopathy, caused by the genetic deficiency of the glycogenolytic 
enzyme myophosphorylase. The enzymatic defect causes the impossibility to mobilize glycogen 
deposits during anaerobic metabolism, the reduction of pyruvate production in the tricarboxylic acid 
   
 
 
 
20 
cycle, and the subsequent oxidative phosphorylation impairment bring to reduction of AcetylCoA 
production, with a cyclic worsening of function of tricarboxylic acid cycle. The disease is clinically 
characterized by childhood-onset of fatigue and exercise induced myalgia, exercise intolerance, 
frequently complicated by episodes of myoglobinuria with acute renal failure due to recurrent 
rhabdomyolysis. Patients usually present the pathognomonic ‘second wind’ phenomenon, that is 
the possibility of patients to continue exercise after some minutes rest, when the pain occurs. It is 
due to the shift to fatty acid oxidation and to the availability of glucose from other sources. A small 
proportion of patients develop a progressive weakness of axial and proximal muscles, especially of 
the upper limbs.  
Diagnosis is based on: i) typical phenotype; ii) grip test: no increase of lactate and hyper-ammonia 
in respone to hand grip effort (Fig. 4); iii) muscle biopsy: increase in glycogen content, typical 
subsarcolemmal vacuolar blebs and no reactivity to myophosphorylase histochemical stain. 
 
 
 
 
 
 
 
Fig.4 Grip-test. Patient installation and blood 
sampling protocol (left) and different profiles of lactate 
and ammonia (right). C (healthy contrls), EI (exercise 
intolerance, non glycogenosis), GSDV (McArdle) and 
Mito (mitochondrial disease). (from Hogrel et al., 
2001) 
C 
EI 
GSDV 
Mito 
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Phosphorylase b Kinase (PHK) Deficiency (Glycogen Storage Disease Type IX):  The 
degradation of glycogen is controlled both in liver and in muscle by a cascade of reactions 
resulting in the activation of phosphorylase, and phosphorylase b kinase (PHK) catalyses the 
conversion of myophosphorylase from the inactive (b) to the active (a) from.  PHK is a 
decahexameric protein composed of four subunits, α, β, γ, and δ. The α and β subunits are 
regulatory, the γ subunit is catalytic, and the δ subunit is a calmodulin and confers calcium 
sensitivity to the enzyme. The hormonal activating signals for glycogenolysis, glucagon and 
adrenaline, activate the membrane-bound adenylate cyclase, which transforms ATP into cyclic 
AMP (cAMP) and interacts with the regulatory subunit of the cAMP-dependent protein kinase, 
resulting in phosphorylation of PHK. Ultimately, this activated PHK transforms glycogen 
phosphorylase into its active conformation, a process that is defective in GSD type IX. 
According to the mode of inheritance and clinical presentation of PHK deficiency six different 
subtypes are distinguished: (1) X-linked liver glycogenosis (GSD IXa), by far the most frequent 
subtype; (2) combined liver and muscle PHK deficiency (GSD IXb); (3) autosomal liver PHK 
deficiency (GSD IXc); (4) X-linked muscle glycogenosis (GSD IXd); (5) autosomal muscle PHK 
deficiency (GSD IXe); and (6) heart PHK deficiency (GSD IXf), which, however is now recognised 
as being due to mutations in the γ2-subunit of AMP-activated protein kinase rather than to PHK 
deficiency. The myopathic variants present in a form that is clinically similar to McArdle disease 
with exercise intolerance, cramps, and rarely recurrent myoglobinuria in young adults (Abarbanel 
et al., 1986; Clemens et al., 1990). Less frequent presentations have been described, including 
infantile weakness and respiratory insufficiency or late-onset weakness. A peculiarity in patients 
with muscular form of PHK deficiency has been the finding of normal lactate and ammonia 
responses on forearm exercise test, which has questioned whether PHK deficiency really is a 
metabolic myopathy. However, muscle morphology most often shows subsarcolemmal deposits of 
normal-looking glycogen. The myopathic form of PHK deficiency is caused by mutations in the 
gene on the X-chromosome for the α-subunit of PHK (PHKA1) (Wehner et al., 1994; Burwinkel et 
al., 2003).   
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Phosphofructokinase deficiency or GSD VII, first described by Tarui (Tarui et al., 1965), is the most 
frequent glycolytic disorder. Phosphofructokinase is a tetrameric enzyme under the control of three 
genetic loci that code for muscle (M), liver (L) and platelet (P) subunits. Mature human muscle 
expresses only a M homotetramer (M4), whereas erythrocytes contain five isoenzymes combining 
the M and the L subunits (Toscano and Musumeci, 2007). There are two main myopathic variants, 
one manifesting as fixed weakness in adult life, although most patients recognise having suffered 
from exercise intolerance in their youth (Danon et al., 1988; Argov et al.,1994); the other affecting 
infants or young children, who have both generalised weakness and symptoms of multisystem 
involvement (Danon et al., 1981; Servidei et al., 1986; Musumeci et al, 2012). In patients with 
typical PFK deficiency, mutations in PFK-M cause total lack of activity in muscle but only partial 
PFK deficiency in red blood cells, where the residual activity approximates 50% and is accounted 
for by the L4 isozyme (Nakajima et al., 2002).  
Other glycolysis enzyme deficiencies are even rarer. Phosphoglycerate mutase (PGAM) 
deficiency has been described in about a dozen patients, and other GSDs in fewer or as single 
cases. Phosphoglycerate mutase (PGAM) is a dimeric enzyme with a muscle-specific (M) and a 
brain-specific (B) subunits. Skeletal and muscle tissues have a marked predominance of the MM 
isozyme, but symptoms only develop in skeletal muscle. The clinical picture is stereotypical: 
exercise intolerance and cramps after vigorous exercise, often followed by myoglobinuria. 
Molecular defects in the PGAM gene have been identified in some patients with GSD X (Vissing et 
al., 1999). 
Phosphoglycerate kinase (PGK) is an ubiquitous enzyme, and clinical presentations of PGK 
deficiency depend on the isolated or associated involvement of three tissues, erythrocytes 
(hemolytic anemia), central nervous system (CNS) (seizures, mental retardation, strokes), and 
skeletal muscle (exercise intolerance, cramps, rhabdomyolysis). PGK is encoded by a X-linked 
gene (PGK1). Approximately ten patients with a myopathic form, with or without haemolytic 
anemia, have been reported (Spiegel et al., 2009).  
Phosphoglucomutase (PGM) catalyses the transformation of glucose-1-phosphate to glucose-6-
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phosphate. Mutations have been detected in the PGM1 gene, coding for the muscle-specific 
PGM1 isoform, in one patient with exercise-induced rhabdomyolysis episodes (Stojkovic et al., 
2009). 
Deficiency in aldolase A (ALDOA gene) is a very rare disorder known to give hemolytic anemia 
(associated with moderate myopathy in few cases). Few patients suffering from isolated recurrent 
episodes of rhabdomyolysis since the age of 2 months, which were invariably triggered by febrile 
illnesses, have been described  (Kreuder et al, 1996; Mamoune et al 2014; Hamel et al, 2015).  
β-enolase (ENO3 gene) deficiency is a very rare enzymatic defect of distal glycolysis, identified in 
few patients who complained of several episodes of rhabdomyolysis, with very aspecific laboratory 
findings (very mild rise in lactate during a forearm exercise test; minimal changes on muscle 
biopsy showed with no lipid or glycogen accumulation) (Comi et al, 2001; Musumeci et al, 2014). 
Lactate dehydrogenase (LDHM gene) deficiency have also been identified in patients with 
exercise intolerance and rhabdomyolysis (Kanno et al.,1995). 
Diagnostic process of muscle glycogenoses 
When a disorder of glycolysis is suspected, routine laboratory results can give few clues guiding toward 
specific diagnoses. These include: 1) an increased bilirubin concentration and reticulocyte count, 
reflecting a compensated hemolysis which may occur in PFK and PGK deficiencies, and 2) an 
hyperuricemia which is commonly found in PFK deficiency and is attributed to excessive purine 
nucleotides degradation in the exercising muscles (Mineo et al., 1985, 1987). Discrepancy between a 
high level of CK and low level of LDH are suggestive of LDH deficiency. The second step in the 
diagnostic process isforearm exercise test for measurement of lactate and ammonia levels: blunted 
lactate production and/or abnormal rise of ammonia levels, are characteristic features of several 
glycogenoses.  Muscle biopsy analysis shows inconstant subsarcolemmal vacuoles and glycogen 
accumulation on PAS stain. This glycogen is normally digested by diastase, excepted in PFK 
deficiency which can also lead to accumulation of abnormally branched glycogen (polyglucosan) 
with a violine aspect on standard Hemateine-Eosine stain and resistance to diastase digestion. 
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Specific anomalies such as tubular aggregates may be observed in PGAM deficiency. A specific 
histochemical reaction is also available for PFK and may help to confirm the diagnosis of GSD VII. 
Conclusive evidence, however, comes from the biochemical analysis of enzyme deficiencies either 
on muscle biopsy for all enzymes, or in erythrocytes for PFK, PGK, and Aldolase A.  
 
Table II. Main clinical and biological features of glycogen storage disorders with exercise 
intolerance (modified with permission from Dr. Laforet, 2012) 
Type
And defective 
enzyme
V (McArdle) Exerc. intolerance, Rhabdomyolysis No lactate increase
Myophosphorylase Second wind Excessive rise of ammonia
VII (Tarui) Exerc. intolerance, No lactate increase Vacuolar myopathy
Phosphofructokinase Rhabdomyolysis, Excessive rise of ammonia Increased PAS staining
Muscle weakness Polyglucosans
Hemolytic anemia PFK stain deficiency
IX Muscle
Phosphorylase b 
kinase Liver
Muscle, 
Erythrocytes
Exerc. intolerance, 
Rhabdomyolysis, No lactate increase
Phosphoglycerate 
kinase CNS Muscle weakness
Excessive rise of 
ammonia
Erythrocytes Hemolytic anemia
X Blunted lactate production Increased PAS staining
Phosphoglycerate 
mutase
Excessive rise of 
ammonia
Tubular aggregates     
((25 % of cases)
XI
Lactate 
dehydrogenase
XII
Aldolase A
XIII Normal PAS staining
β-enolase Negative muscle β-
enolase staining
XIV Normal lactate increase Vacuolar myopathy
Phosphoglucomutase Excessive rise of ammonia Increased PAS staining
Muscle Exerc. intolerance,  Rhabdomyolysis PGM1 (AR)
Muscle Exerc. intolerance, Rhabdomyolysis Not reported Normal PAS staining ALDOA (AR)
Muscle Exerc. intolerance, No lactate increase ENO3 (AR)
Inconstant increased 
PAS staining PGK1 (XR)
Muscle Exerc. intolerance, rhabdomyolysis PGAM (AR)
Muscle Exerc. intolerance,  Rhabdomyolysis
Blunted lactate 
production Normal PAS staining LDH-M (AR)
Muscle, 
Erythrocytes PFK-M (AR)
Exerc. intolerance, 
Rhabdomyolysis
Normal or blunted 
lactate increase
Inconstant vacuolar 
myopathy or increased 
PAS staining
PHKA1 (XR)
Involved 
tissues
Main clinical 
symptoms
Forearm 
exercise test Muscle biopsy
Gene 
(inheritance)
Muscle
Vacuolar myopathy; 
Increased PAS staining; 
Phosphorylase  stain 
deficiency
PYGM (AR)
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B) Disorders of lipid metabolism 
Disorders of lipid metabolism affecting muscle may involve endocellular triglyceride degradation, 
carnitine uptake, long-chain fatty acids mitochondrial transport, or β-oxidation. The pathological 
hallmark of some of these diseases is an increased neutral lipid content, which may be observed 
on muscle biopsies specimen with the specific stainings of Sudan black or oil red O techniques by 
optic microscopy. The term of lipid storage myopathies is often used when the accumulation of 
lipid droplets in muscle fibers is uppermost, and associated with a vacuolated appearance on 
routine histological stains such as hematoxylin and eosin or Gomori Trichrome. Conversely, lipid 
metabolism disorders are inconstantly leading to a muscle lipidosis, and therefore awareness of 
their clinical features and main biological anomalies are essential for establishing accurate 
diagnosis.  
Carnitine palmitoyl transferase II (CPT II) deficiency. Carnitine palmitoyl transferase II (CPT 2) 
deficiency is clinically characterized by muscle stiffness, myalgias, and exercise intolerance and 
episodes of rhabdomyolysis, usually triggered by prolonged exercise, cold, or fasting. 
Very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. Very-long-chain acyl-CoA 
dehydrogenase (VLCAD) deficiency most often occurs in childhood with cardiac or liver 
involvement, but rhabdomyolysis attacks have been increasingly reported in adults (Vianey-Saban 
et al., 1998; Laforêt et al., 2009). The juvenile or adult-onset myopathic form is very similar to CPT 
II deficiency, characterized by recurrent episodes of rhabdomyolysis triggered by prolonged 
exercise, fever, cold or fasting. However, in contrast to adult CPT II deficiency in which the clinical 
features are limited to skeletal muscle, early-onset extra-muscular symptoms may be observed in 
some patients with VLCAD deficiency. Pathologic findings in muscle biopsies are a moderate lipid 
storage in approximately one third of cases, predominating in type 1 fibres. The diagnosis of 
VLCAD deficiency relies on the measurement of plasma or blood spotted onto filter paper 
acylcarnitines by tandem mass spectrometry (MS/MS), allowing the detection of abnormal long-
chain acylcarnitines with tetradecenoylcarnitine (C14:1) as predominant species. Analysis of the 
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ACADVL gene shows a wide mutational spectrum, most of the mutations being private, with a 
clear correlation of genotype with disease phenotype (Andresen et al., 1999). 
Mitochondrial trifunctional protein (MTP) deficiency. Patients with MTP deficiency can be 
classified into two groups: long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) and MTP 
(combined enzyme) deficiencies (Olpin et al., 2005). The majority of MTP-deficient patients have 
an isolated deficiency of LCHAD activity due to mutations in LCHAD domain of the α-subunit 
(HADHA gene). Clinical manifestations are heterogeneous, but similar in LCHAD and MTP 
deficiencies. Severe encephalopathy and hepatopathy may occur in infancy often leading to death. 
A late-onset form may occur later in childhood, which predominant manifestations are 
rhabdomyolysis episodes, cardiomyopathy, pigmentary retinopathy and progressive sensorimotor 
axonal peripheral neuropathy (Spierkoetter et al., 2004). Rhabdomyolysis episodes may be 
induced by exercise, illness or fasting, and are accompanied by life-threatening respiratory failure 
in 45% of patients. The sensorimotor neuropathy is a distinguishing feature which has not been 
reported in patients with other FAO defects, in combination with episodic rhabdomyolysis. Blood 
acylcarnitine profile may show an elevation of long-chain hydroxyacylcarnitines as well as 3-
hydroxydicarboxylic aciduria. A prevalent missense mutation in the LCHAD domain of the α-
subunit (c.1528G>C; p.Glu510Gln) has been identified in approximately 90% of mutant alleles in 
LCHAD deficiency. Unlike LCHAD deficiency, the molecular basis of MTP deficiency is 
heterogeneous with mutations identified in both HADHA and HADHB, the genes coding for the α- 
and β-subunits respectively. 
Medium-chain acyl-CoA dehydrogenase deficiency (MCAD). MCAD deficiciency is the most 
common FAO in childhood (Di Donato and Taroni, 2004). Typical signs and symptoms are 
hyperammonemia,hypoketotic hypoglycaemia, and encephalopathy, of acute onset after a 
prolonged fast of intercurrent infection. Reye-like syndrome, coma, and sudden death may also 
occur in the second year of life. Skeletal muscle disease is very rare, but it seems that some 
patients may develop a mild myopathy with lipid excess in muscle, or rhabdomyolysis episodes 
after strenuous exercise or alcohol ingestion (Ruitenbeek et al., 1995; Lang, 2009). In another 
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hand some MCAD-deficient individuals may remain asymptomatic throughout life. Increased 
octanoylcarnitine (C8) and decenoylcarnitine (C10:1) as well as their corresponding free acids 
(octanoic and cis-4-decenoic acids) are the most useful diagnostic markers in blood, and are also 
detectable in high amounts in urines. Plasma carnitine levels are usually lowered. Genetic studies 
showed that most symptomatic MCAD-deficient patients carry a homozygous c.985A>G 
(p.Lys304Glu) point mutation.  
Multiple acyl-CoA dehydrogenase (MAD) deficiency. MAD deficiency, also known as glutaric 
aciduria type II (GAII), results in abnormal fatty acid, amino acid, and choline metabolism. The 
biochemical abnormalities are explained by deficiency of one of the two electron transfer 
flavoproteins which transfer electrons from acyl-CoA dehydrogenases to the respiratory chain: ETF 
(Electron Transfer Flavoprotein, coded by ETFA and ETFB genes) and ETF-QO (ETF-ubiQuinone 
Oxidoreductase coded by ETFDH gene).  MAD deficiency has a wide range of clinical 
presentations, the most severely affected patients dying in the newborn period of congenital 
anomalies such as cystic renal dysplasia. Milder cases present later in childhood with 
hypoglycaemia, encephalopathy, muscle weakness or cardiomyopathy. Less severely affected 
patients might present with progressive muscle weakness or rhabdomyolysis episodes at adult 
age, and some of these patients show a dramatic response to riboflavin treatment. It has been 
demonstrated that riboflavin-responsive MAD deficiency is associated with mutations in ETFDH 
gene, at least in a large proportion of cases (Olsen et al., 2007). Muscle histology always shows a 
muscle lipidosis. Urine organic acids are most often abnormal at the time of presentation (typically 
with C5 to C10 dicarboxylic aciduria and acylglycine derivatives) and blood acylcarnitine analysis 
shows raised concentrations of all chain lengths acylcarnitines (C4 to C16). Plasma free carnitine 
levels are generally lowered. In addition, probably secondary impairments of respiratory chain 
enzymes deficiencies (RC) have been found in patients for whom such studies have been 
possible. ETFDH pathogenic mutations have also been identified in seven patients who carried the 
diagnosis of myopathic form of coenzyme Q10 deficiency (Gempel et al., 2007). All patients 
presented with fluctuating proximal myopathy, premature fatigue and high CK levels. Triggering 
factors could be infections, fasting, pregnancy or surgery. A dramatic clinical improvement was 
   
 
 
 
28 
noticed in all these patients after CoQ10 and riboflavin supplementation. Riboflavin treatment (100-
400 mg/day) may induce within a few days, a dramatic improvement of muscle symptoms and 
encephalopathy in some patients with riboflavin-responsive MAD deficiency (Olsen et al., 2007). A 
significant improvement of muscle weakness has also been observed after a few months of CoQ10 
supplementation in patients with secondary coenzyme Q10 deficiency, but some of them improved 
even more with combined CoQ10 and riboflavin therapy (Gempel et al., 2007).  Few patients have 
a deficiency that is similar to MAD deficiency but no mutations in ETFA, ETFB, or ETFDH 
identified. Recently, a defect in flavin adenine dinucleotide (FAD) biosynthesis or transportation 
was suspected in one of these MADD patients, which presented a dramatic improvement in the 
clinical and biologic abnormalities after treatment with riboflavine. Two mutations were identified in 
SLC25A32 (solute carrier family 25, member 32) gene, that encodes the mitochondrial FAD 
transporter, an inner mitochondrial membrane carrier that imports FAD from the cytosol into the 
mitochondria (Schiff et al, 2016). 
Phosphatidic acid phosphatase (LIPIN) deficiency. Mutations in LPIN1 gene is an important 
and potentially fatal cause of recurrent episodes of acute myoglobinuria with onset in childhood, 
precipitated by febrile illnesses or anaesthesia (Zeharia et al., 2008; Michot et al., 2010). The 
LPIN1 gene encodes the muscle-specific phosphatidic acid phosphatase (LIPIN), a key enzyme in 
triglyceride and membrane phospholipids biosynthesis, which catalyzes the conversion of 
phosphatidate to diacylglycerol in the triacylglycerol pathway. Age at first episode vary between 15 
months and 7 years, with peak CK levels varying from 20,000 to 450,000 U/l. All the following tests 
give normal results: total and free carnitine, blood acylcarnitine profile, urinary organic acids, and 
FAO studies in fibroblasts or lymphocytes. Muscle biopsy findings usually shows normal lipid 
content or moderate lipid accumulation. 
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Table III. Lipid Myopathies: clinical and molecular features (modified with permission from 
Laforet et al, 2012) 
 
 
 
C) MITOCHONDRIAL MYOPATHIES 
Mitochondrial myopathies due to respiratory chain anomalies rarely manifest as isolated 
rhabdomyolysis. Although some patients present with a clinical phenotype restricted to skeletal 
muscle, multivisceral and central nervous system involvement are generally the main clinical 
features of mitochondrial diseases often named “mitochondrial encephalomyopathies”.  
Progressive external ophtalmoplegia (PEO) is the most frequent skeletal muscle symptom of 
mitochondrial myopathies. Patients with PEO often also complain of exercise intolerance, but 
without important rise of CK levels, nor rhabdomyolysis episodes. However, some mutations of 
Disorder
Main 
neuromuscular 
symptoms
Increase in 
muscle lipid 
droplets
Laboratory features Gene
Normal or moderately 
reduced plasma carnitine 
Increased long-chain 
acylcarnitines (C16, C18:1, 
C18)
Rhabdomyolysis 
episodes
Normal or moderately 
reduced plasma carnitine
Cardiomyopathy
Increased long-chain 
acylcarnitines (C14:1  as main 
species)
Dicarboxylic aciduria 
Rhabdomyolysis 
episodes
Increased long-chain 3-
hydroxy-acylcarnitines HADHA
Cardiomyopathy Dicarboxylic and 3-hydroxydicarboxylic aciduria HADHB
Axonal peripheral 
neuropathy
Proximal and axial 
muscle weakness Low plasma carnitine
Rhabdomyolysis 
(rarely)
Increased acylcarnitines of 
all chain lengths 
2-hydroxyglutaric aciduria +/- 
acylglycines
Muscle weakness Low plasma carnitine
Rhabdomyolysis 
episodes
Increased medium-chain 
acylcarnitines
(C6, C8, C10, C10:1)
Dicarboxylic aciduria + 
acylglycines
Normal plasma carnitine
Phosphatidic acid phosphatase 
deficiency Normal acylcarnitine profile 
Normal urinary organic acids
Medium-chain acyl-CoA 
dehydrogenase (MCAD) deficiency 0 to + ACADM
Very-long-chain acyl-CoA 
dehydrogenase (VLCAD) deficiency 0 to + ACADVL
Mitochondrial trifunctional protein 
(MTP) deficiency 0 to +
Rhabdomyolysis 
episodes 0 to + LPIN1
Multiple acyl-CoA dehydrogenase 
(MAD) deficiency ++ to +++ ETFDH
Carnitine palmitoyl transferase II 
(CPTII) deficiency
Rhabdomyolysis 
episodes 0 to + CPT2
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mitochondrial DNA may manifest by muscle weakness, exercise intolerance, and attacks of 
myoglobinuria (Andreu et al., 1999; Kollberg et al., 2009; Emmanuele et al., 2011). 
- Calcium-reltad myopathies 
The triad (T-tubule and terminal sarcoplasmic reticulum) is the skeletal muscle substructure 
responsible for the regulation of excitation–contraction coupling and intracellular calcium 
homeostasis (Fig. 5). The number of skeletal myopathies caused by gene mutations in 
components of the triad (i.e. RYR1, CASQ1, STIM1 and ORAI1), is rapidly growing, but the clinical 
and molecular features of these diseases are still largely unknown.  
RYR1. Mutations in the skeletal muscle ryanodine receptor (RYR1) gene are a common cause of 
neuromuscular disease, ranging from various congenital myopathies to the malignant hyperthermia 
(MH) susceptibility trait without associated weakness. RYR1 mutations have recently been 
identified as cause for a substantial proportion of patients presenting with unexplained 
rhabdomyolysis and/or exertional myalgia (Sambuughin et al, 2009; Dlamini  et al, 2013; Snoeck et 
al, 2015; Jungbluth et al, 2016; Voermans et al, 2016). This finding further suggest that exertional 
rhabdomyolysis and malignant hyperthermia are overlapping syndromes or slightly different 
manifestations of the same pathological process, recently proposed to be called human stress 
syndrome (Zhao et al, 2014; Snoek et al, 2016) 
CASQ1. Calsequestrin (CASQ) is the main Ca2+ buffering protein in the terminal cisternae of 
sarcoplasmic reticulum (SR) and a regulator of ryanodine receptor (RYR1)-mediated Ca2+ release 
(Kawasaki T, Kasai M, 1994). Mutation in CASQ1 has recently been identified in association with a 
mild vacuolar myopathy in several Italian patients (Rossi et al, 2014; Di Blas et al, 2015).  Its thight 
relationship with RYR1 suggests a potential involvement of mutations in CASQ1 gene in patients 
presenting rhabdomyolysis (see aim 2 of this work).  
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Fig. 5. Representation of calcium 
signaling dynamics in the muscle 
fiber. (From Vallejo-Illaramendi et al, 
2014) 
 
 
 
 
 
 
ORAI1 and STIM1. Signaling through the store-operated Ca(2+) release-activated Ca(2+) (CRAC) 
channel regulates critical cellular functions, including gene expression, cell growth and 
differentiation, and Ca(2+) homeostasis. Loss- and gain-of-function gene mutations in the genes 
encoding the main components of CRAC, ORAI1 and STIM1, in human patients cause distinct 
disease syndromes. Loss-of-function mutations in ORAI1 and STIM1 that abolish CRAC channel 
function and SOCE are characterized by severe combined immunodeficiency (SCID)-like disease, 
autoimmunity, non progressive muscular hypotonia, and ectodermal dysplasia, with defects in 
dental enamel. By contrast, autosomal dominant gain-of-function mutations in these genes result in 
constitutive CRAC channel activation, SOCE, and increased intracellular Ca2+ levels that are 
associated with an overlapping spectrum of diseases, including non-syndromic tubular aggregate 
myopathy (TAM) and York platelet and Stormorken syndromes, two syndromes defined by 
thrombocytopenia, thrombopathy, and bleeding diathesis (Nesin et al, 2014; Endo et al, 2015; 
Lacruz and Feske, 2015).  
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In recent years, the evolution of molecular techniques allowed to develop methods for the analysis 
of exomes ("whole exome sequencing") or of several genes involved in specific diseases ("gene 
panels"). These techniques allowed us to increase the detection rate, reducing time and cost 
analysis, and have identified new genes associated with myopathies. At the same time, it eased 
the identification of genetic variants whose pathogenicity is still doubtful, and it is still far from 
identifying all molecular mechanisms underlying the diseases (Savarese et al, 2014; Kuhn et al, 
2016; Monies et al, 2016). A careful analysis of the clinical picture of the patient, the correct choice 
of diagnostic tools and their careful evaluation is mandatory for the proper selection and 
interpretation of molecular investigations.  
The main objective of this study is, therefore, the evaluation of the diagnostic process of cases of 
rhabdomyolysis, to propose an updated, comprehensive, rational and cost effective protocol based 
on the latest information and techniques.  
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AIM 1 
Identification and characterization of patients referring to 
Neuromuscular Centers for rhabdomyolysis (2000-2016): Clinical 
Features, Diagnostic work-up and final diagnoses 
 
 
RATIONALE 
When facing an episode of rhabdomyolysis, to determine the etiological cause can be extremely 
long, costly and complex. Nevertheless, the correct identification of the underlying cause is of 
utmost importance for correct information regarding prognostic purposes (risk of recurrence) and 
for the family genetic counselling.  
Aims of this first part of the study were therefore: i) to describe clinical features of patients referring 
to tertiary neuromuscular center for rhabdomyolysis not related to clear external causes (such as 
trauma); ii) to evaluate the role of diagnostic tools used to determine molecular basis of 
rhabdomyolysis; iii) to determine the definite diagnostic rate of patients referring for 
rhabdomyolysis; iv) to identify peculiar features of specific diseases manifesting with 
rhabdomyolysis.  
 
METHODS 
A retrospective study was performed, including all patients that referred to the Paris 
Neuromuscular Referral Center for one or more episodes of rhabdomyolysis. The following criteria 
were selected: 
- Inclusion criteria: patients referring from 01.01.2000 to 30.06.2016 for acute rhabdomyolysis, 
defined as: i) acute onset of suggestive signs and symptoms (myalgias /weakness/ dark 
urines) and/or ii) Increase of CK levels > 10 times of rest values.  
- Exclusion criteria: i) diagnosis of muscle disease in the subject or in the family before the 
episode; ii) evidence of external cause of rhabdomyolysis (i.e. epilepsy, surgical intervention, 
trauma). 
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All clinical records and medical dossiers were collected and analyzed, and all the information were 
acquired regarding: 
1. Personal data: age, sex, ethnic origins, familiarity for muscle disease; concomitant 
diseases. 
2. Clinical and laboratory features of the episode(s):  
a. Age at first episode; number of episodes; maximal CK level; type of trigger; time 
relation between trigger and symptoms onset.  
b. Clinical features of the episode: presence of myalgias, weakness, dark urines, 
muscle edema, hyperthermia, other symptoms.  
c. Consequences of the episode: hospitalization, renal insufficiency, dialysis, 
fasciotomy, other. 
3. Clinical and laboratory features during inter-critical periods: CK and lactate levels at 
rest; presence of exercise intolerance, muscle cramps, myalgias, fixed weakness, muscle 
hyper- or hypotrophy, other clinical signs.  
4. Diagnostic tools that were performed:  
a. Standard muscle biopsy: open muscle biopsy followed by histology and 
histochemistry (Haematoxylin and eosin, modified Gomori trichrome, Oil red O, 
periodic acid Schiff, adenosine triphosphatase, combined succinate  
dehydrogenase, cytochrome c oxidase, NADH dehydrogenase, myophosphorylase, 
phosphofructokinase,acid phosphatase, Congo red), Immunohistochemistry (usually 
Dystrophin, , α-, β-, γ− and δ-sarcoglycans, dysferlin, caveolin-3, MHC-1, a-
dystroglycan) and/or Western blot (dystrophin, calpain-3, dysferlin, a-sarcogygan). 
b. EMG protocol: Nerve conduction studies (motor and sensory nerve conduction 
velocity of median, ulnar and peroneal nerves); Repetitive Nerve Stimulation (RNS) 
to test neuromuscular transmission (10 stimuli at 3Hz) in several nerve-muscle 
couples (axillary-trapezius, radial-anconeus, peroneal-tibialis anterior); Needle EMG 
to identify myopathic changes such as abnormal spontaneous activity; short, small 
and polyphasic Motor Unit Action Potential, etc. in proximal (trapezius, deltoid, 
vastus medialis) and distal (extensor digiti communis, tibialis anterior) muscles. 
c. EMG Long Exercise Test (LET): it consists in recording compound muscle action 
potential (CMAP) responses from abductor digiti minimi muscle before and after 5 
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minutes of maximal isometric contraction, to determine sarcolemmal excitability and 
membrane function after effort (see Aim 3 of the present study)   
d. Handgrip test: measurement of blood concentrations of creatine kinase, lactate, and 
ammonia before and after isometric exercise at 70% of the maximal voluntary 
contraction during 30 seconds in non-ischemic conditions. The test was performed 
with standardized procedures in a single-center with specific tool (Hogrel et al, 2001 
and 2015). 
e. Muscle imaging (CT scan or MRI): either lower limbs CT or MRI scan; in selected 
cases whole body MRI. 
f. Profile of acylcarnitines: analyzed by electrospray ionization tandem mass 
spectrometry from plasma or dried whole blood spots (DBS) on filter paper.  
g. Dosage of total and free plasmatic carnitine 
h. Chromatography of urinary organic acid:  studied by gas chromatography-mass 
spectrometry  
i. Dosage of CPT2 activity on lymphocytes: standard procedure of enzymatic dosage 
measurement comparing CPT2 activity to healthy controls and enzymatic reference 
(citrate synthase)  
j. Dosage of beta-oxidation activity on lymphocytes or cultured fibroblasts: dosage of 
fatty acids labeled with 14C ( (1-14C)butyrate , (1-14C)Octanoate, (1-
14C)Palmitate) and Tritium (9,10-3H)Myristate, (9,10-3H)Palmitate) 
k. Dosage of Mitochondrial respiratory chain activity on muscle biopsy: dosage of 
activity of single components of respiratory chain on muscle tissue. 
l. Glyco(geno)lysis on muscle biopsy or blood cells: dosage of glucose-6-phosphate 
dehydrogenase, phosphoglycerate kinase, phoshofructokinase, triose phosphate 
isomerase, lactic dehydrogenase and aldolase on red blood cells or muscle tissue. 
m. Genetic tests: specific candidate gene sequencing (by Sanger Sequencing) or gene 
panels performed in selected cases according to clinical phenotype or results of 
diagnostic tools performed: i) limb girdle muscular dystrophies gene panel (ANO5, 
CAPN3, CAV3, DYSF, EMD, FKRP, SGCA, SGCB, SGCD, SGCG and TRIM32) ; ii) 
Mitocapture panel (mitochondrial diseases gene panel, including 37 mitochondrial 
genes and 101 nuclear genes associated with mitochondrial functioning or disease, 
dr. Jardel, Paris). 
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To identify if different causes of rhabdomyolysis led to episodes with different characteristics, we 
classified the patients in three groups, according to their final diagnosis:  
A) Genetic diagnoses: patients in whom the diagnosis of a genetically caused myopathy was 
posed by genetic, enzymatic or histopathological tests. 
B)  Non-genetic diagnoses: patients in whom a non-genetic diagnosis was confirmed or 
highly suspected, based on clinical and laboratory features. This includes:  
a. Pure exertional rhabdomyolysis and Compartment Syndrome (named together 
“exertional rhabdomyolysis”). Patients in which the cause of rhabdomyolysis was 
attributed to an extraordinary effort and in which muscle pathology was potentially 
excluded. It was defined if: i) episode(s) always related to effort intense / unusual / 
in predisposing conditions; ii) age at first episode > 12 years; iii) no major 
abnormalities on diagnostic tests, iv) no familiar cases.   
b. Drug induced = likely related to statins or other toxic drugs 
c. Inflammatory muscle disease 
d. Infectious disease: likely related to muscular infectious disease 
e. Toxic = likely related to alcohol or drug abuse 
f. Endocrine-related  
g. Other: i.e. rhabdomyolysis induced by Popliteal Artery Entrapment Syndrome 
C) Undiagnosed: patients in which no diagnosis could be obtained. 
In order to identify if specific diseases presented rhabdomyolysis with different characteristics, we 
then compared the features of patients affected by the most recurrent specific diagnosis: McArdle 
disease (Glycogenosis type 5, GSDV), Carnitine-Palmitoil-Transferase 2 deficiency (CPT2), RYR1-
related myopathy, Beker Muscular Dystrophy (BMD), Phosphoglucomutase 1 Deficiency (PGM1), 
Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency (VLCAD), and pure exertional 
rhabdomyolysis or compartment syndrome (“exertional rhabdomyolysis”).  
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We finally reviewed all the diagnostic tools that had been performed to reach the diagnosis in each 
patient, to identify the diagnostic power of each instrument routinely used in the diagnostic workup 
of the specific population of rhabdomyolysis.  
Due to the retrospective nature of this study, despite a homogeneous style in the medical history 
collection, in the evaluation of patients and in the composition of discharge letters, not all 
information was available for all patients. The percentages are thus expressed referring to the total 
of available data and not to the total population. 
 
RESULTS 
Patient population 
By the analysis of databases of Paris-Est Neuromuscular center we identified 208 patients that 
were referred during the period 2000-2016 for one or more episode of rhabdomyolysis, with a 
marked prevalence of males (2.7:1) and a mean age at first consultation of 34.2±12.9 years.  Most 
patients had French origins, but we included patients coming from all over the world (Algeria, 
Antilles, Benin, Brazil, Cameroun, Ivory Coast, Gabon, Ghana, Greece, Guadeloupe, Guinee, 
Guyane, Ile de la Réunion, Iran, Italy, Kuwait, Mali, Morocco, Nigeria, Pakistan, Portugal, Senegal, 
Tahiti, Tunisia, Turkey, USA) 
Clinical features of rhabdomyolysis  
The main features of the episodes of rhabdomyolysis are shown in Figure 7 and Table IV.  Almost 
all patients presented both a marked increase of CK levels and suggestive symptoms of 
rhabdomyolysis. Three patients were completely asymptomatic, and were included because of the 
incidental finding of marked increase of CK levels (up to 12.500, 18.000 and 28.900 U/L 
respectively, with an increase of 60, 150 and 25 times compared to their rest values). In 14 cases 
no maximum CK level was available because it was measured only days after onset or it was 
never measured. Almost half of the patients (n= 99, 47,8%) presented several episodes of 
rhabdomyolises, while 109 (52,2%) presented a single episode of rhabdomyolysis.  In 80% of 
cases a trigger could be identified, and frequently it consisted in different types of effort (figure 7). 
Other triggers included fasting, infectious disease, drugs and cold temperatures.  
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The main symptom of rhabdomyolysis was muscle pain, occurring in 94,4% of our cases; dark 
colored urines were observed only in half of patients. Muscle edema (26%) was almost as frequent 
as muscular weakness (33,7%). Muscular weakness was noticed in 33% of patients; it is to note, 
however, that the presence of muscular weakness can be hidden by the prominent presence of 
muscle pain, that limits movements and interfere with clinical evaluation. The typical clinical triad 
muscle pain + dark colored urines + muscle weakness was noticed only in 18% of cases. Rarer but 
not unique symptoms included hyperthermia (defined as elevated body temperature occurring 
together with or after muscle symptoms) in 13 cases (6,3%), and loss of consciousness (in 5 
cases) sometimes preceded by neuropsychiatric symptoms (confusion, behavior disturbance, in 3).  
 Rhabdomyolyis episodes frequently had major complications, and required immediate and 
intensive medical care (see Table IV). 98 patients (47,4%) required hospitalization, sometimes only 
for rehydration and medical observation. Acute kideny insufficiency (AKI, defined by creatine 
levels) was noticed in 32 cases (15,7%), requiring dialysis in 12 (5,9%). Of note, patients 
presenting acute kidney injury had higher CK levels (mean 224,015 ± 261,133 U/L) than patients 
without AKI (73,939 ± 102,223) but no clear cut-off values could be observed: the range of 
maximum CK levels of patients affected by AKI and non affected by AKI had a great overlap (from 
7.000 to 1.000.000 for AKI, and from 3.200 to 600.000 for patients without AKI). Other rare but 
severe complications included fasciotomy because of compartment syndromes, performed in 9 
patients (anterior leg compartment in 8, linea alba in one) and the rare but severe Posterior 
Reversible Encephalopathy Syndrome (PRESS) following acute kidney injury in one case. No 
precise data could be obtained regarding the type of hospitalization (ICU, medical services, etc), 
the duration of the hospitalization or the type of medical interventions required except for dialysis.  
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Final diagnosis 
The final diagnoses obtained after the work-up are showed in Table V and Figure 8.  A definitive 
diagnosis of genetic disease could be identified in 41 patients (19,7%); a non-genetic diagnosis 
was posed in 49 patients (23,6%) while no diagnosis could be achieved in more than half of our 
population (118; 56,7%). The most frequent genetic causes included GSDV (n = 11), CPT2 (n=11) 
and RYR1-related myopathies (n=8) in the genetic disease category, and pure exertional 
rhabdomyolysis (n = 37) in the non-genetic category.  
Demographical data, features of episodes of rhabdomyolysis and inter-critical characteristics of 
patients grouped according to their final diagnoses are shown in Fig. 9 and Table VI and VII. 
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Table VI. Demographic data and characteristics of the episodes of rhabdomyolysis of patients 
grouped according to the final diagnosis  
Genetic'Diseases Non-genetic'diseases Undiagnosed'pts
n 41 49 118
sex)(ratio)M:F) 27M,)14F)(ratio)1,9) 40M,)9F)(ratio)4,4) 85M,)33)F)(2,6)
Age)1s)consult)(mean)±SD) 33,6)±)14,8 33.8)±)12.5 35,2)±)12,1
Age)1st)episode)(mean)±SD) 22,5)±)14.9 32,1)±)12,3 31,4)±)12,4
n % n % n %
Age)1st)episode <12)ans 10 24,4 0 0,0 3 2,5
13)I)18 12 29,3 3 6,1 15 12,7
19)I)30 10 24,4 26 53,1 41 34,7
31I40 4 9,8 8 16,3 34 28,8
41I50 3 7,3 7 14,3 16 13,6
>50 2 4,9 5 10,2 9 7,6
n.)of)
rhabdomyolysis Single)Episode 14 34,1 36 73,5 59 50,0
Two)Episodes 6 14,6 11 22,4 28 23,7
3I4)Episodes 3 7,3 2 4,1 23 19,5
5)or)more 18 43,9 0 0,0 8 6,8
Max)CK)level <10.000 2 5,9 5 10,2 13 11,7
10)I)49.999 11 32,4 28 57,1 50 45,0
50)I)99.999 9 26,5 6 12,2 16 14,4
100)I)199.999 5 14,7 8 16,3 13 11,7
200)I)499.999 5 14,7 1 2,0 14 12,6
>)500.000 2 5,9 1 2,0 5 4,5
Trigger Yes 34 82,9 48 98 91 77,1
Non)always 3 7,3 0 0 11 9,3
No 4 9,8 1 2 16 13,6
Type)of)triggers Effort 31 64,6 41 80,4 60 56,6
Fever 10 20,8 2 3,9 38 35,8
Drugs 2 4,2 2 3,9 3 2,8
Fasting 3 6,3 0 0 0 0
Other 2 4,2 6 11,8 5 4,7
If)effort:) During)effort 11 42,3 16 41,0 10 18,2
onset)of)symptos Hours)after)effort 14 53,8 17 43,6 33 60,0
Days)after)effor 1 3,8 6 15,4 12 21,8
Clincal'Features'of'
episodes Weakness)(A) 14 35,9 10 20,8 42 37,8
Myalgias)(B) 36 94,7 44 91,7 108 97,3
Dark)colored)urines)(C)) 29 74,4 20 42,6 54 52,3
Muscle)edema 4 10,8 17 38,6 27 26,2
Hypertermia 0 0,0 3 6,1 10 8,5
Clinical'Triad'(#) 3)sypmtoms 10 28,5 3 6,5 24 22,6
2)symptoms 17 48,6 20 43,5 43 40,6
1)symptom 7 20,0 22 47,8 37 34,9
no)symptoms 1 2,9 1 2,2 2 1,9
Consequences Hospitalization 18 43,9 23 46,9 57 48,7
Acute)Kideny)Injury 6 15,0 7 14,3 19 16,4
Dylaisis 2 4,9 2 4,1 8 6,9
Chronic)Kideny)Injury 1 2,4 0 0,0 3 2,6
Fasciotomy 1 2,4 3 6,3 6 5,3
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Table VII. Inter-critical features of patients grouped according to the final diagnosis  
 
 
Patients that were finally diagnosed with a genetic disease presented an earlier first episode of 
rhabdomyolysis, and frequently recurrent episodes. The age at first consultation was not a 
discriminant between the two groups. 
In the “genetic diseases” subset, patients presented episodes with a higher maximum CK level 
compared to patients with rhabdomyolysis due to other causes (in 70% of which CK levels were 
<100,000 U/L). In each category, the effort was the most frequent trigger. Fasting, as trigger, was 
always associated with genetic diseases, while the use of potentially toxic drugs could be the 
trigger of rhabdomyolysis also in genetic diseases. The clinical features of the episodes were 
similar in all categories. However, it is to note that the complete triad muscle weakness + myalgias 
+ dark-colored urines was observed only in 6.5% of patients with non-genetic diseases vs 28% of 
genetic disease.  In the inter-critical period, patients that received a genetic diagnosis presented 
more frequently, but not always, signs and symptoms of a subjacent myopathy (high CK levels, 
exercise intolerance, myalgias, fixed weakness, etc.). 
However, it is important to remind that the vast majority of patients did not obtain a definitive 
diagnosis. The “undiagnosed” group, potentially extremely heterogeneous including both genetic 
and non-genetic diseases, presented the characteristics and clinical features of the other two 
groups.  
Genetic'Diseases Non-genetic'diseases Undiagnosed'pts
n % n % n %
Rest'CK normal((<250) 20 48,8 40 85,1 86 75,4
slightly(elevated((251(>500) 12 29,2 6 12,8 19 16,7
elevated((501(>1000) 5 12,2 0 > 8 7
very(high(>(1000) 4 9,8 1 2,1 1 0,9
Inter'Critical'
Features Exerc.(Intol 24 58,5 6 12,5 38 33
Cramps 12 31,6 5 10,4 21 18,3
myalgias 29 74,4 13 27,1 50 43,1
weakness 8 19,5 1 2,1 13 11,2
Hypo>(or(hypertrophy 3 7,5 2 4,2 9 7,9
other(signs 7 18,9 4 9,1 21 19,1
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The different characteristics of patients affected by the most recurrent specific diagnosis are shown 
in the following figures and tables.  
 
Table VIII. Demographic data and characteristics of the episodes of rhabdomyolysis of patients 
grouped according to their diagnosis 
CPT2 GSDV RYR1 BMD PGM1 VLCAD
Ex.3
Rhabdomyolysis
n 11 11 8 2 2 2 37
Sex 6M;35F 8M;33F 7M;313F 2M 13M;31F 2F 32M;35F
Ratio3M:F 1,2 2,67 7 1 6,4
Age31s3consult3(mean3±SD) 32,5±9,7 41,3±18,8 33,2±10,1 16,65 28 n.a. 32,2±12,1
Range 16,73S45,9 18,13S72,2 20,63S40,6 173;316,3 20,2;335,8 NA,325,7 17,23S360,5
% % % % % % %
Age$1st$episode <123ans 63,6 0,0 0,0 50,0 50,0 0,0
133S318 27,3 27,3 25,0 100,0 50,0 50,0 2,8
193S330 9,1 36,4 37,5 63,9
31S40 0,0 18,2 12,5 13,9
41S50 0,0 9,1 25,0 11,1
>50 0,0 9,1 0,0 8,3
n.$of$rhabdomyolysis Single3Episode 9,1 36,4 50,0 100,0 75,7
Two3Episodes 9,1 18,2 25,0 50,0 21,6
3S43Episodes 27,3 0,0 0,0 2,7
53or3more 54,5 45,5 25,0 50,0 100 0,0
Max$CK$level <10.000 0,0 14,3 0,0 50,0 50,0 8,1
103S349.999 0,0 28,6 37,5 50,0 100 50,0 56,8
503S399.999 33,3 14,3 25,0 16,2
1003S3199.999 22,2 28,6 12,5 16,2
2003S3499.999 33,3 14,3 12,5 2,7
>3500.000 11,1 0,0 12,5 0,0
CPT2 GSDV RYR1 BMD PGM1 VLCAD
Ex.3
Rhabdomyolysis
Weakness 45,5 22,2 25,0 50,0 50,0 13,9
Myalgias 100 100,0 75,0 100,0 100,0 100,0 88,9
Dark3Urines 90,0 90,0 37,5 50,0 50,0 50,0 45,7
Muscle3Oedema 0,0 22,2 12,5 50,0 40,6
Hyperthermy 0,0 0,0 0,0 8,1
Hospitalization 45,5 45,5 75,0 50,0 48,6
Acute3Kidey3Injyr 18,2 27,3 12,5 13,5
Dyalysis 9,1 9,1 0,0 2,7
Chronic3renal3disease 0,0 0,0 0,0 0,0
Fasciotomy 0,0 0,0 12,5 5,6
Clincal$Features$and$
consequences$of$
episodes
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Table X. Inter-critical features of patients grouped according to their final diagnosis. Rest CK levels 
distinguish GSDV patients (invariably elevated) from the other groups, presenting normal or slightly increase 
of CK levels.  
 
 
 
 
 
 
 
 
 
 
GSDV patients presented more homogeneous and identifiable clinical and laboratory features. In 
inter-critical period (usually since childhood) they presented the typical exercise intolerance, 
associated with myalgias and in 16,7% of cases the pathognomonic “second wind” phenomenon”. 
Rest CK level was invariably above normal limits (even >1000 U/L). First rhabdomyolysis occurred 
more frequently in the 2nd-3rd decades, and was frequently recurrent. The trigger was always 
exercise, except in one case that was triggered by concomitant statin use. Typical feature is 
muscle oedema, occurring more frequently than in other disases. 
CPT2 patients presented the earliest episodes of rhabdomyolysis (always 1st – 2nd decade), 
usually triggered by effort or infectious diseases or fasting, recurrent, and characterized by very 
high CK levels (>50,000 U/L). During inter-critical periods no weakness was observed, and 
generally muscle symptoms were rare except for muscle pain. CK levels were normal to slightly 
elevated.  RYR1 mutated patients frequently did not present myopathic signs in inter-critical 
periods (no muscle signs or symptoms, normal CK level). Rhabdomyolysis occurred in 2nd -5th 
decade, usually triggered by effort or fever, and was characterized by very high CK levels. In 50% 
of patients a single episode of rhabdomyolysis was reported. All these features make the diagnosis 
between RYR1-mutated patients and “pure exertional rhabdomyolysis” patients impossible, based 
only on clinical features. 
CPT2 GSDV RYR1 BMD PGM1 VLCAD
Ex.3
Rhabdomyolysis
% % % % % % %
Rest%CK%values normal:3<250 81,8 0 62,5 100 100,0 85,7
slightly3elev3(2513N500) 18,2 36,4 37,5 100,0 14,3
high3(5013N1000) 0,0 36,4
very3high3(>31000) 0,0 27,3
Inter/critical%
features exercise3intolerance 36,4 90,9 37,5 50,0 100 100,0 8,1
cramps 20,0 36,4 25,0 50,0 100,0 10,8
myalgias 80,0 90,9 50,0 50,0 100 100,0 24,3
weakness 0,0 36,4 0,0 50,0 50,0 0,0
hypo3or3hypertrophy 0,0 9,1 0,0 5,4
other3signs 0,0 16,7 25,0 50,0 0,0
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Diagnostic tools 
The retrospective analysis of diagnostic tools’ results performed in patients affected by different 
disease are shown in Figure 11.  
The EMG is frequently the first exam performed in the diagnostic work-up of suspected 
myopathies. However, in patients with rhabdomyolysis, the exam results frequently normal 
(85/109, 78%) and rarely shows non specific myopathic signs (19/109, 17,4%), irrespective of the 
final diagnosis. The relevance of this exam can be increased with provocative tests, as the Long 
Exercise test, that in most GSDV and in one PGM1 patient shows a peculiar pattern of immediate 
decrease of CMAP (Compund Muscle Action Potential) after effort, indicating a post-exercise 
muscle cells unexcitability (see aim 3 of this thesis for further information). The handgrip test 
shows a peculiar and pathognomonic result in GSDV patients (no lactate increase and 
hyperammonia after effort, 100%, n =6)), and isolated post-exercise hyperammonia in PGM1 
patients (100%, n =2).  The profile of acylcarnitines is useful in the diagnosis of lipid disorders, 
showing recurrent patterns in CPT2 patients (increase in C16, C16:1 and C18:1 with reduction of 
the final product of beta-oxidation C2: found in 3/7 CPT2 patients, 43%) and VLCAD (increase in 
C14 and C14:1, found in 2/2 patients); the isolated increase of long chains is more unspecific 
(secondary beta-oxidation dysfunction?), but do not exclude the diagnosis of CPT2 (observed in 
4/7 CPT2 patients, 58%).  
The muscle biopsy shows several and different types of abnormalities in every groups.  In GSDV 
(9/9 biopsies) muscle biopsy showed typical vacuolar blebs, increase in glycogen content and 
absence of myophosphorylase, in PGM1 (2/2) increase of glycogen content and in BMD (2/2) mild 
dystrophic changes, with abnormal IHC/WB of dystrophin protein.  CPT2 and RYR1 muscle 
biopsies show more variable abnormalities, ranging from normal to lipid accumulation, mild 
unspecific myopathic changes, glycogen accumulation, or consequences of rhabdomyolysis. 
Finally exertional rhabdomyolysis (ER) muscle biopsy showed subtle histopathological 
abnormalities.   
Other diagnostic tools performed include:  CPT2 dosage on white blood cells (abnormally reduced 
in 8 cases/87 studied); beta oxidation activity on lymphocytes or cultured fibroblasts (abnormal but 
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non pathognomonic in 2/11 patients); dosage of mitochondrial respiratory chain activity on muscle 
biopsy (isolated complex defect in 5 and global reduction of activity in 2 undiagnosed patient, 
normal activity in 12); study of glyco(geno)lysis enzyme on muscle biopsy or blood cells (isolated 
enzymatic defect in 2 and global reduction of activity in 2 undiagnosed patient; 2 
myophosphorylase deficiency; 14 normal tests); halothane and caffeine in vitro muscle contracture 
tests (normal in 2 ER and 1 undiagnosed patients, abnormal in 1 undiagnosed patient – not 
studied for RYR1 mutations). 
The genetic tests performed are shown in Table XI. A total of 102 test were performed, 37 of them 
resulting positive (for 4 patients with confirmed genetic no genetic data were available, and the 
diagnosis was based on biochemical analysis). More specifically, the most frequent test performed 
was CPT2 gene, which resulted positive only in 6/27 patients (22,2%). PYGM gene was studied in 
patients highly suggestive of GSDV, based on clinical features or diagnostic tools results, thus 
gene mutations were always identified (10/10 patients). RYR1 was routinely studied only in recent 
years, and resulted positive in a high percentage of patients (33%, 8/24). Genetic panels for limb 
girdle muscular dystrophies (LGMD, Dr F. Leturcq) and mitochondrial myopathies (Mitocapture, dr 
C. Jardel) were developed in the last few years, and were used in selected cases. Only the 
Mitocapture identified a new pathogenic mutation in DNA2 gene in one case.  
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Table XI. Genetic test performed and 
% of positive results. CPT2 and RYR1 
were the most frequently studied genes; 
PYGM and ACAVDL genes, when 
performed, always resulted mutated.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11 (In the next page). Diagnostic tools results in patients classified according their final 
diagnosis (ER = exertional rhabdomyolysis): Standard EMG/ENG (A), EMG-Long Exercise Test (B), 
Handgrip Test (C), profile of acylcarnitines (D) and Muscle Biopsy (E). EMG is normal in majority of 
patients, otherwise presenting mild non specific myopathic signs (A). EMG with long exercise test detected 
an early decrease in post-exercise CMAP in >70% of GSDV patients and one PGM1 (B, see aim 3 of the 
present work). The handgrip test shows a typical profile in 100% of GSDV patients (no lactate increase + 
hyperammonia); all PGM1 patients presented the more aspecific reduced increase in post-exercise ammonia 
(C). The profile of acylcarnitines was useful in diagnosis of CPT2 and VLCAD (D). Muscle biopsy showed the 
typical GSDV profile in all GSDV patients, a mild dystrophic pattern in all BMD patients; in other diseases, it 
was more variable and less useful in guiding diagnosis.  
Abbr.: ER = Exertional Rhabdomyolysis 
n"of"test positive %positive
CPT2 27 6 22,2
RYR1 24 8 33,3
PYGM 10 10 100,0
MELAS/MERRF 8 0 0,0
DMD 6 2 33,3
LPIN1 4 1 25,0
PGM1 3 2 66,7
ACAVDL 2 2 100,0
DMPK 2 1 50,0
FSHD 2 0 0,0
ANO5 1 0 0,0
CACNA1S 1 0 0,0
CNBP 1 1 100,0
FKRP 1 1 100,0
GeneBPanelBMito 3 1 33,3
GeneBPanelBLGMD 1 0 0,0
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Relevant Cases 
Few specific cases of this cohort need to be discussed individually for their clinical features or 
diagnosis.  
S.D (F, 53 years) presented with two episodes of rhabdomyolysis (max CK 15,000 and 37,000 
U/L) over 2 years, the first triggered by an infectious disease and the second by an effort (1h 
tennis). CK levels never lowered to normal values (rest CK 1,000 – 2,000), and the patient 
reported exercise intolerance and muscle pain. The diagnosis of myeloma stage 1 (IgG k) was 
posed after the identification of monoclonal peak, soon after the first episode. In the following 
months the patient was treated for the hematologic disease, but she reported persistent exercise 
intolerance, myalgias and high CK levels. The most frequent metabolic myopathies and 
dystrophies were excluded. The identification of immunoglobulin deposition on the muscle 
membrane was confirmed on the first biopsy (otherwise showing only small foci of necrosis-
regeneration). This suggested a direct correlation between myopathy and myeloma, as previously 
reported in few sporadic cases (Rodolico et al, 2006).  
L.S. (F, 35 years) presented several episodes of rhabdomyolysis with max CK levels 19,000 U/L, 
without any evident trigger. Out of the episode, she reported only frequent and persistent muscle 
pain, and CK levels at rest were slightly elevated (400 U/L). All diagnostic tests were normal 
(muscle biopsy, several EMG, acylcarnitines, GAA activity); however, on one EMG the neurologist 
reported one or two doubtful myotonic discharges. For this reason, genetic test for myotonic 
dystrophy type 1 and 2 were performed, and the CCTG amplification on ZNF9 gene was identified. 
To our knowledge, this is the first report of rhabdomyolysis in myotonic dystrophy type 2. 
B.D, (M, 23 years) first consulted a neurologist after a rhabdomyolysis with CK >58,000 U/L after a 
body building training. Clinical evaluation showed distal weakness on upper limbs and distal 
hypotrophy on lower limbs, associated with hand myotonia. Genetic analysis confirmed the 
diagnosis of DM1 (230 CTG repeats on DMPK gene).  
D.J. (M, 46 years) first consulted because the acute onset of myalgias, weakness and dark urines 
after a moderate effort; CK level was 11,400 U/L; no AKI sings were noted.  Clinical features 
(proximal upper limbs muscular weakness, skin rush) and histopathological features led to the 
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diagnosis of dermatomyosytis.  Dermatomyosytis manifesting with rhabdomyolysis is rarely 
reported, and need to be carefully recognized, monitored and treated (i.e. steroids) because of its 
frequent and severe complications (AKI).  
 Q.G. (M, 33 years), affected by sickle cell trait, presented several episodes of bilateral pain and 
muscle edema, both localized in anterior and lateral compartment of legs, appearing invariably 
during prolonged walking; in several occasion (the most intense) high CK levels were detected (> 
12,000 U/L).  Muscle biopsy, EMG and muscle MRI were not diriment.  Lower limbs arteriography 
with plantar flexion showed a narrowing of the left popliteal artery, thus suggesting a popliteal 
artery entrapment syndrome associated with the known risk factor for rhabdomyolysis, the sickle 
cell trait (Connes et al, 2015; Nelson et al, 2016). 
B.S (F, 41 years), reported since childhood several episodes suggesting rhabdomyolysis (muscle 
pain, dark urines), usually triggered by exercise or fasting. She was hospitalized for the first time at 
the age of 40, because of intense and diffuse pain and functional impairment after a prolonged 
walk. CK levels were 21,000 U/L. Few days later, despite accurate treatment (rehydration, 
hemodialysis because of anuria), she presented tonic-clonic seizures associated with muscle pain 
and stiffness, posterior headache, visual disturbances, difficulty in reading and low-grade fever. 
Cerebral MRI showed signs compatible with PRES (Posterior Reversible Encephalopathy 
Syndrome) related to AKI. Clinical and radiological findings normalized few weeks later and the 
patients did not present any consequences. In the same days she received the diagnosis of CPT2 
deficiency. 
R.A (M, 69 years) consulted for an episode of rhabdomyolysis triggered by an infectious disease 
(CK 91,000). Inter-critical CK level was normal. He presented high blood lactate (4,1 Mmol/L), 
deafness, bilateral ptosis, without any other myopatic sign/symptom.  Muscle biopsy was 
unspecific. Mitochondrial DNA analysis showed the presence of multiple deletions, 
MELAS/MERRF mutations were absent, and the gene panel for mitochondrial diseases 
(Mitocapture) identified one pathogenic mutation in DNA2 gene.  
In four patients the diagnostic workup after the episode of rhabomyolysis let to the identification of 
asymptomatic cardiomyopathy (2 dilated cardiomyopathy and 2 left ventricular dysfunction); 
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muscle biopsies showed mild myopathic signs in 1, glycogen accumulation in 1, and were normal 
in 2. Despite the diagnostic workup none of them received a final genetic diagnosis.  Cardiological 
investigations are thus indicated in all cases of rhabdomyolysis. 
 
 
 
COMMENT 
Several previous studies reviewed the clinical features of rhabdomyolysis, its pathomechanisms, 
causes and treatments (Warren et al, 2002; Khan, 2009; Torres et al, 2015; Chavez et al, 2016). 
Most of the works were performed in the setting of Internal Medecine Services or Emergency 
Rooms, and thus included mainly secondary causes of rhabdomyolysis, such as trauma, surgery, 
endocrine pathologies or drugs. Other studies were focused on exertional rhabdomyolysis in 
healthy people, such as military trainees or sporty subjects (Nelson et al, 2016). A recent study 
tried to describe the characteristics of potential myoapthic patients among subjects presenting 
rhabdomyolsys (Scalco et al, 2016).  
The aim of this part of the study was to evaluate the clinical features, diagnostic work-up and 
diagnostic yield in a large series of non-selected patients referred for rhabdomyolysis to a 
Neurmouscular Center in the last 16 years.  In this retrospective work we collected a large 
population of patients referred for rhabdomyolysis to a Referral Center for Neuromuscular 
disorders, thus including all the potentially myopathic patients that manifested with this dramatic 
event. Due to the setting of the study (Neuromuscular Center) and the inclusion criteria, we 
excluded all the evident secondary causes of rhabdomyolysis. The main limitation of this study is 
its retrospective nature, and its results reflect the clinical variability in diagnostic process and not a 
predefined common protocol. However, to minimize this hurdle the study was conducted in a single 
center, in which few experts in neuromuscular diseases work and collaborate in a rather 
homogenous way. This smoothen the potential variability of the diagnostic processes.  
During the study period, new information was obtained in the evolving world of metabolic 
myopathies. For example, a great number of new genes were discovered, or were identified as 
associated with rhabdomyolysis (i.e. RYR1, in the last few years); new diagnostic techniques were 
developed or improved (i.e. handgrip test, EMG provocative test, gene panels); or abandoned (i.e. 
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halothane and caffeine in vitro muscle contracture tests for hyperthermia). As such, this study 
includes patients that underwent different diagnostic processes  that were always the most up-
dated for the time of study.  
In the present study we confirm that rhabdomyolysis can be a dramatic event, that frequently 
requires a rapid and intensive medical care (almost 50% of patients required hospitalization), it is 
frequently recurrent, and can be complicated by acute kidney injury, compartment syndrome 
requiring fasciotomy (9 cases) or even Posterior Reversible Encephalopathy Syndrome due to AKI.  
Rhabdomyolysis has a major impact on quality of daily life of patients (risk of recurrence, fear of 
efforts or fever, etc) and on families (is there a genetic disease underlying this event?).  
In the present study we demonstrate that, in case of, rhabdomyolysis the etiological diagnosis is 
still very challenging, when an external cause is not evident.  Only 20% of the included patients 
received a final diagnosis of genetic disease, while 23% received a diagnosis of non-genetic cause 
of rhabdomyolysis. However, it has to be noted that the last category included mostly the so called 
“pure exertional rhabdomyolysis” (ER); this entity is a diagnosis per exclusionem, posed when a 
peculiar effort alone is thought to be the cause of rhabdomyolysis. However, here we demonstrate 
that RYR1-related rhabdomyolysis patients were clinically not different from ER patients.  They 
were normal in the inter-critical periods, presented frequently isolated episodes of rhabdomyolysis, 
triggered by effort. RYR1 was found mutated in one third of the examined patients, thus it can be 
considered as a frequent cause of rhabdomyolysis and need to be studied in all patients. RYR1-
related rhabdomyolysisdiagnosis has several implications for prognosis (risk of recurrence, risk of 
general anesthesia, etc) and for genetic counseling (autosomal dominant transmission).  
The clinical features of the episodes or the inter-critical clinical and laboratory features could guide 
toward specific molecular diagnoses only in few cases. GSDV is the easiest diagnosis, because of 
the typical clinical features and the unique results of diagnostic work up. CPT2 need to be 
suspected when the trigger is a long effort, or fasting, or fever. VLCAD is suspected when the 
profile of acylcarnitines is supportive of the diagnosis, if normal  it should be repeated during 
episodes or after prolonged fasting (8 hours).  Overall, the vast majority of patients presenting to 
neuromuscular specialists for rhabdomyolysis do not receive a final diagnosis (118, around 50%) 
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despite an extensive work up. This work-up is expensive and time consuming for patients and 
doctors, and it is still insufficient for the diagnosis of rhabdomyolysis.   
The Next Generation Sequencing (NGS) techniques applied to the whole exome, or to gene 
panels can study several genes implicated in specific diseases in a single procedure. In France 
several panels were set up, including one for limb-gridle muscular dystrophies (LGMD), and one 
for mitochondrial disease (Mitocapture). These panels are used in standard diagnosis of genetic 
diseases, and were used also in specific cases of rhabdomyolysis, when indicated. A gene panel 
specific for metabolic myopathies with rhabdomyolysis is actually under development and it will be 
discussed in aim 4 of this thesis.  The NGS techniques are very promising for increasing the 
diagnostic rate of patients presenting with rare diseases, however can not be blindly used as a first 
step in a diagnostic work-up, but need to be implemented after a careful selection of candidates 
and after the exclusion of: i) genetic diseases specifically suggested by first-step exams; ii) non-
genetic diseases that can be excluded by first-step exams.      
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AIM2: 
Identification and characterization of a new cause of rhabdomyolysis:  
CASQ1-related myopathy 
 
 
RATIONALE 
Ca2+ transients are crucial second messengers during excitation-contraction (EC) coupling in the 
skeletal muscle. Synchronous Ca2+ release from the sarcoplasmic reticulum (SR) terminal 
cisternae (TC) into the muscle fibre cytoplasm, and its subsequent re-uptake into the SR store, is 
granted by a structural and functional unit of Ca2+ sensors, release channels, buffering proteins 
and ATP-dependent Ca2+ pumps, usually referred to as triad (Rossi AE and Dirksen RT, 2006), 
spanning from the lumen of SR, across the cytoplasm and into the extracellular matrix. A number 
of Ca2+ handling diseases involving components of triad junction have been recently described 
(Dowling et al, 2014). They  underline  the importance of its single constituents in maintaining a 
correct Ca2+ homeostasis and release/uptake dynamics for a proper function of muscle tissues. 
Calsequestrin (CASQ) is the main Ca2+ buffering protein in the terminal cisternae of sarcoplasmic 
reticulum (SR) and a regulator of ryanodine receptor (RYR1)-mediated Ca2+ release (Kawasaki T 
and Kasai M, 1994). Its two isoforms, CASQ1 and CASQ2, are preferentially expressed in skeletal 
and cardiac/smooth muscle tissues, respectively, with CASQ1 being largely predominant isoform 
in fast twitch (type II) fibres (Lamboley et al, 2013). CASQ1 buffers the Ca2+ present in the SR 
terminal cisternae and prevents it from precipitating, thus maintaining a large-capacity buffering 
gradient that can rapidly release large amounts of Ca2+ upon stimulus. CASQ1 is physically 
anchored to RYR1 through the interaction with triadin and junction (Zhang et al, 1997), and 
proposed to act as an SR Ca2+ sensor and regulator of Ca2+-release kinetics by RYR1. CASQ1 
binds Ca2+ ions with high capacity both through high- and low-affinity binding sites. Occupancy of 
high- and low-affinity sites promotes step-wise polymerization of CASQ1 proteins in long chains, 
which are further stabilized by coordinate binding of additional Ca2+ ions between its adjacent 
chains. High dissociation rate of CASQ1 low-affinity Ca2+ binding sites assures that release of non-
bound, free TC Ca2+ easily destabilizes the CASQ1 polymeric network, resulting in a precise 
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kinetics of Ca2+ release (Sanchez et al, 2012). Thus, both Ca2+ binding residues and those 
involved in CASQ1 polymerization have an important role in regulating the kinetics of Ca2+ 
buffering and release.  
The physiological importance of CASQ1 is underlined by the findings from CASQ1 null mice, which 
undergo spontaneous lethal episodes, similar to human malignant hyperthermia (MH), when 
exposed to stressful conditions (e.g. mating, heat shock, anaesthetics) (Dainese et al, 2007). iIn 
these mice, fast-twitch muscle (e.g. EDL) of male display SR Ca2+ depletion and signs of Ca2+ 
leakage at increasing temperatures (Protasi et al, 2011), which might be the basis of spontaneous 
contractures seen in the lethal episodes of CASQ1 KO mice.  
Despite this crucial role, the first human myopathy associated with CASQ1 mutations was only 
recently reported by two Italian groups (Rossi et al, 2014; Di Blasi et al, 2015).  The 
authorsdescribed a common CASQ1 mutation, p.Asp244Gly, in patients presentinga non-
debilitating vacuolar myopathy, first described at the histopathological level by Tomelleri et al. 
(2006). The p.Asp244Gly mutation identified was shown to impair CASQ1 polymerization 
dynamics and, consequently, the Ca2+ release kinetics (Rossi et al, 2014; Di Blasi et al, 2015, 
D’Adamo et al 2016).  The Asp244 amino-acid is located in a a conserved high-affinity Ca2+-
binding site of CASQ1. Another group reported a positive correlation of CASQ1 single nucleotide 
polymorphism (SNP) 175A>G with the onset of heat stroke in a cohort of 150 patients (Li et al, 
2014)  
In this study we report the clinical and molecular characterization of the largest cohort of CASQ1 
mutated patients, including 16 patients carrying the common p.Asp244Gly mutation (two already 
described [9]) and one patient carrying a novel CASQ1 mutation (p.Gly103Asp), identified by 
genetic screening of unresolved vacuolar myopathies. We expanded the clinical spectrum of the 
disease, identify a peculiar muscle MRI pattern, and further deepened molecular, 
immunohistochemical and ultrastructural characterization of muscle biopsies, thus providing new 
details on the pathogenetic aspects of this myopathy.  
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METHODS 
Informed consent and ethics 
Every patient signed an informed consent to collect and study biological material and clinical data. 
The study was carried out in accordance with the ethical rules and guidelines issued by the Ethical 
committee of Azienda Ospedaliera di Padova and by Helsinki declaration. The collection of muscle 
biopsies was conducted as part of standard diagnostic procedures. 
Participants 
All patients with genetically unresolved vacuolar myopathy with histopathologcal features similar to 
those described in the report of Rossi and colleagues (2014) were selected from the database of 
patients referring to the Centre for Muscle Diseases at University Hospital of Padova and 
underwent the genetic screening for CASQ1 gene mutation. Histopathological selection criteria 
included: i) presence of optically empty vacuoles and/or amorphous material debris; ii) absence of 
rimmed vacuoles; iii) no other causes of myopathy (i.e. normal muscular protein levels and acid 
maltase level; no exposure to chloroquine or colchicine). Forty five unrelated patients (38 males 
and 7 females) were included in the study.   
Genetic Analysis 
Genomic DNA was extracted from peripheral blood leucocytes by standard salting out procedure. 
Tetraprimer ARMS (Amplification Refractory Mutation System) were designed to verify the 
presence of c.731A>G variant and positive results were confirmed by Sanger sequencing (primers 
and PCR conditions available on request).  
Total RNA was isolated from patients’ skeletal muscle biopsies following the TRIzol (Life 
Technology) standard protocol, and RNA was reverse-transcribed using SuperScript™III Reverse 
Transcriptase (Life Technology).  CASQ1 cDNA (NM_001231) was amplified and coding sequence 
analyzed by Sanger sequencing. Any variation was checked against public databases (dbSNP, 
Exome Variant Server and 1000Genomes) to take note of common SNPs. Potential functional 
effects of the novel variants were evaluated using in silico prediction tools: MutationTaster 
(http://www.mutationtaster.org/), SIFT (http://sift.jcvi.org/), and PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/). Haplotype analysis was based on genotyping of four 
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dinucleotide polymorphic repeats in a region of about 400 kb around CASQ1 gene (see 
Supplementary material for haplotype analysis procedure; and Supplementary Table I for primer 
sequences). 
Clinical Evaluation 
The clinical features and progression of CASQ1-mutated patients were evaluated by revision of 
medical records, structured questionnaire and direct specific clinical evaluation.  Patients were 
interviewed about family history, clinical course, type and age of disease onset and rate of 
progression. The clinical features were classified by the presence of clinical signs and symptoms, 
like tendon contraction, muscular hypo- or hypertrophy, scoliosis, scapular winging, dysphagia. 
Muscle weakness was evaluated by manual muscle testing and graded according to Medical 
Research Council score from 0 (absence of any contraction) to 5 (normal strength).  
Patients underwent a cardiac evaluation that included physical examination, electrocardiography 
(ECG) and echocardiography including M-mode, two dimensional, and Doppler echocardiography 
to detect the presence of abnormal wall motion and regional structural abnormalities. 
A complete respiratory evaluation including physical examination, arterial blood gas analysis and 
spirometry in upper position was performed. 
Muscle Imaging 
Patients underwent muscle MRI assessment (1.5 T, Avanto, Siemens, Erlangen, Germany) with 
T1-weighted axial scans and Short-Tau Inversion Recovery (STIR) sequences. The examination 
included pelvic, lower and upper limbs muscles.  The degree of degeneration and fatty infiltration 
was graded in T1-weighted axial scans by experienced radiologists according to Mercuri’s 
classification. A final score ranging from 1 (normal) to 4 (severe involvement) was assigned to 
each muscle. Hyperintense signals in STIR sequences were used to assess the degree of 
oedema, and graded into 3 levels (absent, mild or  moderate). 
Histology and fluorescence microscopy 
At the time of diagnosis vastus lateralis biopsies were obtained from 10 patients. Serial 
cryosections of muscle biopsies were stained with hematoxylin–eosin (H&E), ATPase, NADH and 
antibodies against the components of calcium homeostasis machinery (CASQ1, RYR1, SERCA1, 
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STIM1, ORAI1 and SERCA2) (see supplementary material for details about antibodies and 
procedures). Single fibers were followed throughout serial sections, counted and distinguished for 
the fiber type, presence of single or multiple vacuoles and immunoreactivity of the vacuoles for 
each indicated antibody.   
Electron Microscopy 
Ultrathin section of muscle specimens was fixed in glutaraldehyde and osmium tetroxide and 
contrasted with 4% uranyl acetate and lead citrate and examined with a transmission electronic 
microscope (TEM Philips 410 T) (See supplementary material for details). 
 
RESULTS 
CASQ1 gene mutation analyses 
Forty five unrelated patients were tested for the presence of c.731A>G (p.Asp244Gly) variant, and 
the mutation was identified in 10 subjects in heterozygous state. The collection of more detailed 
information about the pedigrees identified others 6 affected family members that were recruited in 
the study. Overall we identified the common c.731A>G (p.Asp244Gly) mutation in 16 patients 
belonging to 9 unrelated pedigrees.   
The hypothesis of a common ancestor origin for p.Asp244Gly mutation was confirmed by 
reconstructing the haplotype using four polymorphic dinucleotide repeats mapping on chromosome 
1q23.2 near CASQ1 gene (400Kb). The specific haplotype was shared by all analyzed family 
members  and segregated with p.Asp244Gly mutation (Figure 12), confirming the hypothesis of a 
common ancestor of all Italian patients and consistently with the previously published studies.  
Screening of the entire CASQ1 gene sequence was performed in patients resulting negative for 
the p.Asp244Gly variation. This technique revealed a new heterozygous variant, c.308G>A, in one 
patient. This variation has never been reported previously in public genetic databases of genomic 
variants (dbSNP, 100Genomes, EVS), and determines an amino acid change from highly 
conserved glycin to aspartic acid at codon 103 of the protein (p.Gly103Asp).  
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Clinical evaluation 
Seventeen CASQ1-mutated patients were included in the study (14 males, 3 females) (Table XII). 
Age at last evaluation ranged from 16 to 83 years (mean 54±18). Seven patients aged 33 to 71 
years were still asymptomatic, and the diagnosis was posed because of asymptomatic 
hyperCKemia (7 patients) or because relatives of symptomatic patients.  In the remaining patients, 
first symptoms occurred at an age of 47 ± 18 years (range 15 -70). First reported symptoms 
included exercise intolerance (4 cases), muscle pain (4), proximal weakness in lower limbs (3) and 
frequent falls (2). Of note, three patients reported minimal symptoms since childhood (running and 
sport difficulties, scoliosis), even if overt disease manifested in the third or fourth decade. CK levels 
at disease onset or before first symptoms were elevated in all patients at rest, ranging from 1.5 to 
11 times above normal values (mean x7,5). Rhabdomyolysis episodes were reported in 3 cases 
after efforts (myalgias and increase of CK levels up to x21 normal value). All patients were 
ambulant without aids at last evaluation. 
Neurological evaluation showed normal muscle strength in 9/15 patients in upper limbs muscles 
and in 10/15 patients in lower limb muscles. In the remaining patients muscle weakness was 
always mild to moderate (3+ to 4+/5 MRC scale) and was observed more frequently in triceps 
brachii (5 cases), scapular muscles (4), biceps brachii and deltoid (1) in upper limbs, and hip 
flexors (5 cases), knee flexors (3), knee extensors and ankle dorsiflexors (1) in lower limbs.  Two 
patients presented mild neck flexor weakness. Muscle trophism was normal in 6 patients, while the 
others presented scapular winging (6 cases), quadriceps hypotrophy (4 cases) or pectoral 
hypotrophy associated with distal lower limbs hypotrophy (3 patients). Knee deep tendon reflexes 
were brisk in 7 patients. Two patients presented mild joint contractures (knee and elbow). 
Pneumological evaluation revealed a mild decrease of respiratory muscle strength in two patients 
(mild reduction of maximal inspiratory and expiratory pressure). Cardiac evaluations showed a 
non-physiological left ventricular concentric remodeling in patient n. 17 (59 years, no risk factors, 
no neuromuscular signs except for high CK levels) and hypertensive heart disease in patient n. 9 
(79 years). No cardiac abnormalities were observed elsewhere. No cases of malignant 
hyperthermia were reported. 
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Muscle imaging 
Ten patients (median age 48, range 16 – 79) underwent a muscle MRI of upper and lower limbs 
(Figure 13 and 14). The four youngest patients (aged between 16 and 37) showed normal signal in 
T1-weighted sequences. In the remaining patients, a peculiar pattern of fibro-fatty substitution was 
observed, with severity of degeneration correlated with the age.  First alterations appeared in the 
distal portion of vastus lateralis, in semitendinosus muscle and in gluteus maximus. With 
increasing patients’ age, the fibro-fatty substitution spread to all anterior thigh muscles, with 
relative sparing of vastus intermedius, to posterior thigh muscles with relative sparing of sartorius 
and proximal portion of biceps femoris, and to posterior leg, more severe in gastrocnemius. Of 
note, a remarkable asymmetry was observed in all patients. In upper limbs, only the two oldest 
patients presented mild involvement of triceps brachii (2/2) and deltoid and subscapularis (1/2).   
STIR sequences revealed mild intrafascicular oedema in all patients with a variable distribution: 
gastrocnemius in three patient, posterior thigh muscles in two patients, anterior thigh muscles 
(vastus lateralis and rectus femoris) in one patient and  triceps brachii in one patient. 
For two patients a radiological follow-up was available. Patient n. 1 showed a mild evolution 
(Mercuri score changed from 1 to 2a) of fibro-fatty involution during a four-year observational 
period (from 48 to 52 years). One patient (n. 9) underwent to MRI at age of 77 and 78. The severe 
fibro-fatty substitution at baseline was unchanged after one year. 
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Fig. 13 Lower Limb Muscle MRI, T1W sequences in three patients of different age. Age-dependent and 
asymetric degree of fibro-fatty substitution can be observed initially in the distal portion of vastus lateralis, 
semitendinosus muscle and in gluteus maximus, the spreading to all anterior thigh muscles (with relative 
sparing of vastus intermedius), to posterior thigh muscles (with relative sparing of sartorius and proximal 
portion of biceps femoris), and to posterior leg (more severe in gastrocnemius). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14. Upper Limb Muscle MRI, T1W and STIR sequences in the two oldest patients.  
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Histopathology and Immunofluorescence 
Serial cryosections of nine patients carrying the p.Asp244Gly and one patient with p.Gly103Asp 
mutation in CASQ1 gene were analyzed for histological properties and distribution of the proteins 
involved in maintaining Ca2+ homeostasis in muscle fibers. On average, 116±59 of fibers were 
analyzed per patient. As already described by Rossi et al (2014), p.Asp244Gly mutation in CASQ1 
resulted in the appearance of optically empty vacuoles in H&E staining as well as in acidic ATPase 
(pH 4.35). We also observed increase in fiber size variations (6-86 µm), rare necrotic fibers, central 
nuclei, splitting and activation of acid phosphatase. Immunofluorescence analysis of sarcoplasmic 
Ca2+ influx/efflux machinery proteins showed that the optically empty vacuoles did not show any 
reactivity within the vacuoles, but rather displayed enrichment in fluorescence signal on the 
vacuole margins (RYR1, ORAI1, SERCA1, SERCA2 and STIM1) or in the sarcoplasmic tubular 
network surrounding the vacuoles (CASQ1). Vacuoles were observed almost exclusively in fast 
twitch type II fibers (204/488 type II fibers with vacuoles, versus 4/557 type I fibers with vacuoles) 
and most of the fibers contained multiple vacuoles (82±14% of all vacuolated fibers). CASQ1 and 
SERCA1 displayed the highest levels of enrichment (respectively in 86±16% and 74±20% of type II 
vacuolated fibers), while lower levels of enrichment on vacuole margins were observed for ORAI1 
(72±30%), RYR1 (60±23%) and STIM1 (57±33%).  The weakest increase in signal and the 
smallest frequency of enrichment of vacuoles was seen for SERCA2, normally expressed at low 
levels in fast twitch fibers (38±18% of vacuolated fibers). (Fig 15). 
The novel missense mutation p.Gly103Asp resulted in a different muscle morphology, showing 
either vacuoles fulfilled of amorphous material (in 15/62 fibers) or NADH-positive debris (in 10/62), 
without any optically empty vacuole. As for the p.Asp244Gly biopsies, abnormalities were 
observed in type II fibers only. The intra-fiber vacuoles were strongly immunoreactive for CASQ1, 
ORAI1, RYR1, SERCA1 and STIM1 and weakly reacting with SERCA2. 
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Fig. 15 Histopathology and immunofluorescence. Serial cryosections of one patient carrying the 
p.Asp244Gly mutation (A) and one patient with p.Gly103Asp (B). 
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COMMENT 
Rossi et al. (2014) and Di Blasi et al. (2015) described the first cohorts of patients affected by 
CASQ1-related myopathy, clinically characterized by high CK levels, mild proximal weakness and 
myalgias, thus confirming the important role of CASQ1 in muscle calcium homeostasis. The 
disease was associated with a typical histopathological picture with at the EM level inclusions of 
different size and shape.  In the original reports all patientscarried the same mutation c.731A>G 
(p.Asp244Gly) suggesting a founder effect in northern Italy. In our study we expand the clinical and 
molecular characteristic of the disease associated with the common p.Asp244Gly mutation and 
confirm the slow progression of the disease and the paucity of symptoms at onset that can be 
complicated by an increased disability due to the progressive course of muscle weakness in later 
age. Furthermore, we identified a peculiar muscle MRI pattern and a novel CASQ1 gene mutation 
leading to a different histopathological picture. 
The CASQ1 genetic screening in unresolved vacuolar myopathies referred to our Unit confirmed 
the high prevalence of CASQ1 mutations (11/45; 24%). The identification of the recurrent 
p.Asp244Gly in 16 patients and the haplotype study confirm the presence of a founder effect in 
Italian patients, and in particular in patients coming from the north-eastern part of our region 
(Veneto). The haplotype reconstruction identified unknown family linkages in our patients cohort.  
We also identified a novel CASQ1 mutation, p.Gly103Asp, in a patient coming from a region 
(Tuscany) of central Italy. The pathogenicity of the common mutation was previously demonstrated 
by several genetic and in vivo approaches (Rossi, DI Blasi, D’Adamo), but the pathogenicity of the 
newly identified mutation can only be inferred because no patient’s cultured muscle tissue was 
available for functional studies. We think this mutation may be pathogenetic because a) it is has 
never been reported in genetic databases (dbSNP, 1000Genomes, EVS) including the newly 
launched Genome Aggregation Database of the Broad Institute including 126,216 exome 
sequences and 15,136 whole-genome sequences from unrelated individuals sequenced as part of 
various disease-specific and population genetic studies (http://gnomad.broadinstitute.org/); b)  it is 
located in a highly conserved residue. Two in silico prediction tools suggest a pathogenic role 
(MutationTaster indicate as highly probable the damaging effect, p=0.999; same results with SIFT) 
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and only one tool (Polyphen2) indicates a possible benign effect; c) the glycine in position 103 is 
located in an important functional domain of the protein, a [Ca2+] independent high affinity Ca2+-
binding site, suggesting that a mutation in this region is probably damaging; and d)the clinical 
features of the patient (myalgias, exercise intolerance, hyperCKemia) are consistent with the other 
CASQ1-mutated patients. 
In our case series the clinical onset typically occurs on the 3rd-4th decade with relatively mild 
symptoms, such as myalgias, exercise intolerance or mild proximal weakness, and the clinical 
evolution is usually slow. HyperCKemia is common and sometimes the unique clinical sign, 
confirming that the disease can be frequently undiagnosed and that the condition could be more 
frequent than supposed. However, our study suggests that caution should be put in deriving long 
term prognosis in these patients since in the oldest patients the disease evolves in a slowly 
progressive proximal and axial myopathy. Indeed in our case series we identified some patients 
presenting with unrecognized clinical symptoms since the very young age, indicating a very early 
subtle onset, and older patients presenting with severe muscular weakness significantly affecting 
motor function.  Muscle MRI studies further confirm the progression of the disease toward severe 
fibro-fatty substitution. The recurrence of rhabdomyolysis in three case (marked increase in CK 
levels and myalgias after effort) and the exercise intolerance indicate that CASQ1 myopathy 
should be classified also as a metabolic myopathy with dynamic symptoms, sometimes without 
fixed weakness.  
The clinical features in our case series were quite homogeneous. Muscular weakness was 
relatively mild and age-dependent, and mostly involved triceps brachii and scapular muscles in 
upper limbs, hip and knee flexors in lower limbs. We frequently observed muscle hypotrophy 
involving quadriceps, scapular muscles or pectoral muscles. This is different from the cohort 
described by Di Blasi et al (2016), in which two patients, aged 29 and 81 years, presented with 
mild muscle hypertrophy. Interestingly, an accurate neurological examination showed brisk knee 
reflexes in 7/15 patients, a sign unfrequently observed in myopathic patients with quadriceps 
involvement. This feature could indicate a possible role of CASQ1 in central nervous system.  The 
clinical “red flags” that have to be taken into account for diagnosing CASQ1-related myopathy are 
   
 
  71 
proximal and axial muscular weakness, with scapular winging and quadriceps hypotrophy with 
relative sparing of rectus anterior, brisk patellar reflexes, mild contractures (ankle, but also knee 
and wrist), and very high CK levels. The diagnosis of CASQ1 myopathy can also be suspected on 
the basis of the peculiar MRI pattern. The asymmetric age-dependent fibro-fatty substitution of 
distal portion of vastus lateralis, semitendinosus, gluteus maximus and gastrocnemius medialis, 
with relative sparing of vastus intermedius, sartorius and proximal portion of biceps femoris is 
recurrent in our case series. 
In one patient left ventricle concentric remodeling was observed in the absence of other known 
causes. This patient did not show any neuromuscular sign / symptom except for high CK levels. 
The association between heart disease and CASQ1 to date has never been described, and 
CASQ1 is not highly expressed in heart.  A single case observation cannot lead to definitive 
conclusions, but, if confirmed, could help to extend the phenotypic spectrum of disease. 
Furthermore, this finding indicates the necessity for careful monitoring of cardiac function in all 
CASQ1-mutated patients. 
The most important clue for the diagnosis of CASQ1-related myopathy is the histopathological 
picture. In p.Arg244Gly mutated patients it is always characterized by myopathic changes and 
vacuolar inclusions, optically empty in standard colorations. These vacuoles strongly react with 
antibodies against SR calcium-machinery proteins. This finding suggests that abnormal 
polymerization and aggregation of mutated CASQ1 lead not only to a decreases the release of 
Ca2+, as previously reported (D’Adamo et al, 2016) but also to accumulation of all the other 
interacting proteins.  
The slow evolution of the CASQ1-myopathy could be due to redundance of the complex molecular 
mechanisms regulating calcium homeostasis that can supply the abnormal functioning of 
calsequestrin, and that still need to be further investigated. The triadopathies are muscle 
pathologies that include an emerging group of diseases due to genetic defects in one of the 
components of the triades (RYR1, ORAI1, STIM1, CASQ1). These pathologies frequently present 
with overlapping phenotypic and molecular and histopathological characteristics, that are being 
clarified in the recent few years. Each gene may be associated with different clinical pictures, but 
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similar histopathological changes can be caused by mutations in different genes. For example, 
myalgias or recurrent rhabdomyolysis can be observed in CASQ1 but also in RYR1 and ORAI1-
related myopathies (Dlamini et al, 2013, Endo et al, 2014). In these myopathies histopathological 
features are different, being characterized either by core-like structures on oxidative stains (RYR1) 
or by the presence of tubular aggregates (ORAI1) or vacuolar inclusions (CASQ1). Our patient 
presenting the p.Gly103Asp CASQ1 mutation showed NADH-positive inclusion on muscle biopsy, 
thus further blurring the boundaries of our actual knowledge.  
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Supplementary material 
- Haplotype study  
Supplementary Table 1: Primer sequences 
PRIMER NAME SEQUENCE (5’-3’) 
chr1_160402793F TGTAAAACGACGGCCAGTTATGAGACTAGGGCCCTCGT 
chr1_160402793R GGCAAGCATGGTTAGGATCTG 
chr1_160082463F TGTAAAACGACGGCCAGTAGTGTTGTCCTCTCCCCTGA 
chr1_160082463R AAAGCAGGAGGATGGAAGGC 
chr1_160019166F TGTAAAACGACGGCCAGTTGGCACCGCTCTTAGTACAT 
chr1_160019166R CCTGGCCCTATGATGATGGA 
chr1_160008864F TGTAAAACGACGGCCAGTTAGACAGCAGGGGAATGGGA 
chr1_160008864R GACCCATGATCACCACCAACT 
 
Procedure: starting position of the 4 dinucleotide polymorphic repeats: 160402793, 160082463, 160019166, 
160008864 on chromosome 1.  Each forward primer is tailed with an M13 sequence and a third primer 
(M13F with fluorescent dye) is used in the PCR reaction to obtain fluorescent PCR products as previously 
described (Schuelke M. , 2000). PCR products is then pooled and separated on an ABI PRISM 3700 DNA 
Sequencer (Applied Biosystems, Foster City, CA). The physical positions of each microsatellite is based on 
the UCSC Human Genome Database (http://genome.ucsc.edu, hg19). 
 
Immunofluorescene studies 
Antibodies: mouse monoclonal calsequestrin (Thermo Fisher, Waltham, MA, USA, clone VIIID12); ryanodine 
receptor, RYR1 (Abcam, Cambridge, UK, clone 34C), SERCA1 (Santa Cruz, CA, USA, clone VE121G9); 
STIM1 (BD, San Jose, CA, USA, clone 44/GOK), rabbit polyclonal ORAI1 (Sigma-Aldrich Srl, Milan, Italy); 
goat polyclonal SERCA2 (Santa Cruz, N19).   
 
Procedure: muscle cryosections were collected on Superfrost slides, fixed with 4% paraformaldehyde (PFA) 
for 10 minutes, permeabilized with 0.3% Triton X-100, incubated in blocking solution (0.5% BSA, 10% horse 
serum in PBS) for 30 min and incubated with antibodies at 4°C overnight (0.5% BSA, 2% horse serum in 
PBS). Anti-goat Cy2-coniugated (Jackson Laboratory, Sacramento, CA, USA), anti-mouse Cy3-coniugated 
or anti-rabbit Cy3-coniugated (Invitrogen, Carlsbad, CA, USA) secondary antibodies were incubated (0.5% 
BSA, 2% horse serum in PBS) at RT for 1h. Slides were mounted using Vectashield medium with DAPI stain 
(Vector, Burlingame, CA, USA) and examined on upright microscope (Olympus BX60, Tokyo, Japan) 
equipped with a CCD camera (DP70, Olympus). Images were post-processed using ImageJ suite. 
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AIM 3 
Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E 
 
 
RATIONALE 
Sarcoglycanopathies are four recessive limb girdle muscular dystrophies (LGMD) that 
represent 20-25% of all Limb-Girdle Muscular Dystrophies (LGMDs) and 40-65% of LGMD cases 
with infantile onset (Vainzof et al, 1999; Fanin et al, 2009).  Sarcoglycanopathies are caused by 
mutations in genes encoding four transmembrane glycoproteins, α-, β-, γ-, and δ-sarcoglycan, that 
form a tetrameric complex at the cell membrane of skeletal and cardiac muscle. Sarcoglycans play 
an important role in stabilizing the dystrophin-associated glycoprotein (DAG) complex localized in 
the sarcolemma of muscle fibres  (Ervasti et al, 1990; Chan et al , 1998; Hack et al, 2000; 
Sandonà et al, 2009).     
Mutations in individual sarcoglycans are responsible for LGMD2C (γ-sarcoglycan, SGCC 
gene at 13q12) (Noguchi et al, 1995), LGMD2D (α-sarcoglycan,SGCA at 17q219) (Roberds et al, 
1994),  LGMD2E (β-sarcoglycan, SGCB at 4q12) (Bonnemann et al, 1995; Lim et al, 1995) and 
LGMD2F (δ-sarcoglycan, SGCD at 5q33) (Nigro et al, 1996).  LGMD2C and 2D are the most 
frequent and extensively studied of the four sarcoglycanopathies, with a clinical phenotype 
characterized by progressive skeletal muscle weakness ranging from a severe Duchenne-like 
dystrophy to a relatively mild LGMD (Eymard et al, 1997; Angelini et al, 1995; Ozawa  et al, 2005; 
Nalini et al, 2010; Ferreira et al, 2011).  LGMD2E is a rare cause of sarcoglycanopathy, with an 
estimated prevalence of 0.86 x10-6 cases (Fanin et al, 1997), and has generally been believed to 
be associated with a severe skeletal muscle phenotype, and cardiomyopathy (Melacini et al, 1999; 
Barresi etal, 2000; Politano et al, 2001; Fanin et al, 2003).  One case of exercise-induced 
myoglobinuria as presenting sign of primary beta-sarcoglycanopathy has been reported (Cagliani 
et al, 2001). Rhabdomyolysis in other sarcoglycanopathyies (LGMD2D and LGMD2C) has been 
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described, thus indicating that sarcoglycan genes should be added to the differential diagnosis in 
the work up of rhabdomyolisis, exercise intolerance, and hyperCKemia, even in the absence of 
overt muscle weakness or with normal α-sarcoglycan immunohistochemistry in muscle biopsy 
(Mongini  et al, 2002; Pena  et al, 2010; Ceravolo  et al, 2014; Tarnopolsky et al, 2015). However, 
knowledge about the specific features of LGMD2E is scarce, because no large cohort has been 
reported. 
 The aim of this part of the study was to detail the specific clinical pattern of LGMD2E (age 
of onset; clinical course; rate of progression; skeletal muscle involvement; rate of rhabdomyolysis; 
and heart and respiratory function) from a large population of patients affected by LGMD2E. We 
also evaluated biochemical and molecular data, to identify possible correlations between 
phenotype, genotype, and protein expression levels and to recognize prognostic factors.   
 
MATERIAL AND METHODS 
Study design and patient cohort  
The study was designed as an observational, cross-sectional study of clinical features and natural 
course of LGMD2E.  All patients diagnosed with LGMD2E underwent an extensive clinical 
evaluation and an accurate revision of medical records was performed.  
The clinical characteristics at time of diagnosis and the progression of the disease were evaluated 
by the revision of medical records and by the administration of a specific questionnaire.  Patients 
were divided in three subgroups according to phenotype, defined as “severe” or “mild” if loss of 
ambulation occurred before or after 18 years of age. The phenotype of patients younger than 18 
years and still ambulant was defined as “unknown”. 
Clinical evaluation of muscle function 
Family history, consanguinity and medical history were recorded for each patient.   Patients were 
asked about the first symptoms of the disease, and age of onset.  The progression of muscle 
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weakness was described by noting the age of loss of specific functions: running, climbing stairs, 
rising from a chair, and walking without support.  The presence and the age of onset of clinical 
signs and symptoms were recorded (weakness, muscle pain, etc).  All the CK measurements 
available were also reported. Muscle weakness was evaluated by manual muscle testing and 
graded according to Medical Research Council score from 0 (absence of any contraction) to 5 
(normal strength).  Fifteen muscle groups of proximal and distal limbs and axial muscles were 
selected for statistical analysis.  
Evaluation of cardiac function 
Symptoms and signs of cardiac involvement were noted.  Patients underwent cardiac evaluation, 
including physical examination, electrocardiography (ECG) and echocardiography.  All rhythm 
abnormalities were noted. Echocardiographic examination included M-mode, two dimensional, and 
Doppler echocardiography to detect the presence of abnormal wall motion and regional structural 
abnormalities in both ventricles and to measure cardiac volumes and ejection fraction.  
Evaluation of respiratory function 
The respiratory section of the questionnaire investigated signs and symptoms of chronic 
respiratory insufficiency, such as rest or exercise dyspnoea, morning headache and recurrent 
pneumonia and ineffective cough.  The number of hospitalization for acute respiratory insufficiency 
was recorded. Use of a mechanical respiratory support, either invasive or non-invasive, was noted, 
as well as the number of hours of ventilation per day.  The respiratory evaluation included 
assessment of sitting vital capacity and arterial blood gas analysis.  
Sarcoglycan proteins studies 
At the time of diagnosis, an open skeletal muscle biopsy was obtained after informed consent from 
patients or their parents.  Muscle biopsies were performed in 23 patients, and 
immunohistochemistry and/or western blot studies of muscle proteins were available for 20 cases. 
The level of sarcoglycans was assessed by visual inspection using a panel of monoclonal 
antibodies (Novocastra, Newcastle- upon-Tyne, UK) and scored as “normal”, “slightly reduced”, 
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“markedly reduced” or “absent”. The skeletal muscle samples used as controls were obtained from 
patients free of any neuromuscular disorder. 
SGCB gene analyses 
All patients and their parents gave informed consent for the molecular analysis of SGCB gene. The 
identification of SGCB gene mutations was obtained by single-strand conformation polymorphism 
(SSCP)/direct sequencing or direct sequencing of genomic DNA extracted either from muscle or 
blood leucocytes.   
 
RESULTS 
Patient cohort 
Thirty-two patients from 25 families (16 males and 16 females) were included (19 from Italy, 7 from 
Denmark, and 6 from France).  According to phenotype classification, 15 patients were scored as 
severe, 12 as mild, and 5 as “unknown”, because younger than 18 and still ambulant.  The age at 
last evaluation ranged from 7 to 67 years. Most patients were of Caucasian descent (15 from Italy, 
7 from Denmark, 3 from France, 1 from Albania and 1 from Greece); three unrelated patients 
originated from the Tunisian Sephardic Jewish community, two siblings were Jordanian and one 
patient came from the Ivory Coast.  Consanguinity was reported in seven families.  Two patients 
were deceased: a severe patient at the age of 14 due to cardiac failure, and a mild patient at 60 
from pneumonia.  
Muscle function 
The main clinical symptoms are listed in Table XIII.  The progression of motor impairment is 
represented in Figure 16. The age at onset ranged from 1.5 to 40 years.  The first symptoms 
occurred before age 10 in all severe patients.  At onset symptoms were predominately in pelvic 
girdle muscles, with difficulty in running (41%), gait abnormalities (34%), and difficulties in rising 
from the floor (22%). Three patients had been diagnosed at a pre-symptomatic stage due to  
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Table XIII. Patient population and clinical features
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incidental finding of increase of CK levels.  All severe patients were wheelchair bound, in 
accordance with the definition of severe phenotype, at a mean age of 13 years (range 9-17).  Age 
at loss of ambulation was between 23 and 59 years in the five mild patients (mean 40 years). The 
decline of muscle function was homogeneous and rapid in the severe patients, mimicking the 
course of Duchenne muscular dystrophy.  Mild patients showed a more variable course of the 
disease (Figure 16). Frequent clinical signs included calf hypertrophy (78% of patients), tiptoe gait 
pattern (56%), tendon contracture (69%), scapular winging (59%), and scoliosis (59%).  No 
patients reported dark colored urines, myalgias, transient weakness associated with increase of 
CK level  triggered by exercise, fever or other and thus no episode of rhabdomyolysis could be 
clearly identified. However,muscle pain was reported in 75% of mild, 40% of unknown phenotype, 
and never in severe cases. Macroglossia was found in 31% of patients, with almost double the 
prevalence in severe vs. mild cases.  Neurological examination showed proximal muscle 
weakness in all patients, predominantly in lower limb muscles (Figure 17). Muscle weakness was 
more diffuse in severe patients, involving both proximal and distal muscles of lower and upper 
limbs. Distal muscles were severely affected only in patients with severe or unknown phenotype. 
Axial muscle weakness was found in 22 of 25 examined patients (88%).   
 
Fig. 16. Clinical 
Progressoin in 
LGMD2E, evaluated 
by ad hoc 
questionnaires 
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Fig. 17. Muscle involvement in LGMD2E: muscle strength measured with MRC score.  
 
 
 
Cardiac function 
Cardiac involvement was found in 20/32 patients (11/15 severe, 7/10 mild and 3/5 unknown).  
Cardiac involvement was independent of skeletal muscle phenotype. Dilated cardiomyopathy was 
detected in six cases, localized wall motion abnormalities in eight, and hypertrophic 
cardiomyopathy in two.  Conduction or heart rhythm abnormalities were reported in 9 patients, 
including right or left bundle branch block, third degree AV block, supraventricular arrhythmia, 
ventricular tachycardia, and ventricular ectopic beats (Table XIII).    Frequent signs and symptoms 
included palpitations (9 cases) and lower limb oedema (5).  One patient required pacemaker 
implantation. One patient, affected by dilated cardiomyopathy, had experienced cardiac arrest at 
54 years and was resuscitated.  One patient presented symptomatic ventricular ectopic beats at 
the age of 16, without any further cardiologic alteration until the latest echocardiography evaluation 
at age of 34.  Sixteen patients (7 severe, 7 mild and 2 unknown phenotype) received cardiac 
treatments (ACE inhibitors, beta-blockers, diuretics), most often with a combination of two or more 
drugs (Table XIII).   
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Respiratory function  
Details on respiratory symptoms are reported in Table XIII.  Six patients (19%) presented 
respiratory insufficiency requiring invasive mechanical ventilation (3 severe, 1 mild) or non-invasive 
ventilation in 2 cases (1 severe and 1 mild).  Age at mechanical ventilation ranged between 22 and 
45 years (median: 39) for severe patients and 38 and 44 years for mild patients (Figure 16). 
Spirometry data were available for 22 patients (9 severe, aged 18.9±7.7; 10 mild, aged 40,7±15.3; 
3 unknown,11.2±4.4 ). Forced vital capacity did not differ significantly among the different 
phenotypes (60 ± 26 % of predicted value in severe patients, 71 ± 33 % in mild patients and 67 ± 6 
% in unknown phenotype patients). 
Sarcoglycan proteins studies 
Sarcoglycan imunofluorescence and immunoblotting analyses were available in twenty patients 
(Table XIV).  Deficiency of one or more sarcoglycans was obvious in the muscle biopsy of all 
patients.  In eight patients (seven severe, one unkown) the deficiency of α, β-, γ-, and δ-
sarcoglycan was complete. Two other severe patients had complete deficiency of one or more 
sarcoglycans.  No patients presenting with a mild phenotype had a complete deficiency of 
sarcoglycans. Among the milder patients, a variable reduction of sarcoglycans was observed.   
In order to test the hypothesis that a complete vs partial reduction of β -sarcoglycan level be 
associated with a more or less severe phenotype, a time-to-event analysis of loss of ambulation 
(using age as a time variable) was carried out comparing patients with absence or partial 
expression of b-sarcoglycan protein.   The Kaplan-Meyer survival curve for loss of ambulation 
comparing patients with complete (n=9) or partial (n=9) defect of β -sarcoglycan is shown in Figure 
18. Median ages at loss of ambulation were compared between the two groups by log-rank test. 
The median age at loss of ambulation was significantly lower in patients with observed absence of 
protein (13 years) compared to residual protein expression (50 years) (p<10-4). 
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Fig. 18. Time-to-event analysis of loss of 
ambulation comparing presence or absence of 
sarcoglycan protein on muscle tissue . In case of 
absence of  the protein, median age of loss of 
ambulation is predicted to occur at a median age of 
13 years, while if a residual level of protein is 
present the loss of ambulation is predicted to occur 
at a median age of 50 (p<10-4). 
 
 
 
 
SGCB gene analyses 
Both SGCB mutated alleles were identified in all patients. Seventeen different mutations were 
found: seven missense, two nonsense, one splice site and seven frame-shift insertion/duplication 
or deletion (Table XIV).  Five mutations were novel:c.518_519insC, c.543C>G, c.754_957del, 
c.36_37delinsG, c.1A>G. Three mutations were recurrent. The 32 bp duplication in exon 1 (c.- 
22_10dup; p.Ala8Glyfs*22), corresponding to 16% of the mutated alleles, predicted a mild 
phenotype being found only in mild patients (3 from Tunisia, one from Italy and one from Ivory 
Coast). The 8 bp duplication in exon 3 (c.377_384dup; p.Gly129Glnfs*2; 20% of mutated alleles) 
was detected only in  severe patients (5 homozygous and 3 compound heterozygous with other 
null mutations). The c.341C>T (p.Ser114Phe) was observed in 6 cases (14% of mutated alleles; 3 
homozygous and 3 compound heterozygous) that presented with a clinical phenotype classified 
either as severe or mild. 
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Table XIV. Correlations between genotype, protein expression and phenotype. 
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COMMENT 
For rare diseases, small patient populations limit the ability to collect valid data, which inhibits 
progress in research and care. This limitation can be effectively overcome by collaborative efforts 
among specialized centres sharing experience in clinical evaluation and management of such 
patients.  The aim of this study was to collect accurate clinical, genetic and protein expression data 
in a large number of LGMD2E patients and thereby learn the clinical features of the disease, and in 
particular the occurrence of rhabdomyolysis. We also evaluated whether there exists any 
genotype/phenotype correlation, and whether prognostic factors can be identified.  Four tertiary 
referral centres contributed to the data collection, and report the largest series of LGMD2E patients 
to date.   
Muscle weakness in LGMD2E, as expected, predominates in proximal muscles, with a more sever 
affection of lower vs. upper limbs.  However, a distal involvement is frequent and prominent in 
severe form, even at the early stages of the disease (ankle dorsiflexion and wrist extension), as 
well as axial weakness.  This peculiar pattern of muscle involvement could help in differentiation 
between a severe or mild phenotype since early stages of the disease. Calf and tongue 
hypertrophy is frequent.  LGMD2E patients often present tiptoe walking due to Achilles tendon 
contractures appearing early in the disease, and subsequently develop contractures in elbows and 
knees.   
In the present cohort we never detected episodes of rhabdomyolysis, clinically or biochemically 
defined.  However, muscle pain was frequently reported in “active patients”, and in particular in 
75% of mild patients and 40% of unknown phenotype, while it was never reported in severe cases 
(non ambulant). The presence of this symptom only in active patients suggests that the defective 
membrane could be challenged only in mobile patients and therefore in this category of patient if 
the stress is sufficient may potentially result in rhabdomyolysis 
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In the present study we also observed that cardiac involvement is frequent in LGMD2E, affecting 
more than 50% of patients as reported in previous studies (Barresi et al, 2000; Politano et al, 2001; 
Fanin et al, 2003). Cardiac involvement was independent of skeletal muscle phenotype and 
occurred at all stages of the disease, even before skeletal muscles were affected. This 
discrepancy is surprising, but has been reported for related muscular dystrophies with cardiac 
involvement (Melacini et al, 1996).  It is usually characterized by a dilated cardiomyopathy 
preceded by localized wall motion abnormalities or fibrosis signs on ECG studies.  In our cohort, 
two patients were affected by hypertrophic cardiomyopathy, but the correlation with β-
sarcoglycanopathy is doubtful because of concomitant hypertension in one case and lack of follow-
up in the other.  Heart rhythm and conduction abnormalities were also frequent in LGMD2E (28% 
of patients).  Heart conduction disturbance in LGMD2E has been reported before, and was usually 
observed after diffuse myocardial involvement (Melacini et al, 1999; Fanin et al, 2003).  In our 
series, at least two patients presented either symptomatic ventricular ectopic beats or right bundle 
branch block before the onset of other overt cardiac involvement, suggesting the need for close 
monitoring of cardiac function in LGMD2E.   
A severe respiratory involvement requiring mechanical ventilation is less frequent, occurring in the 
later stages of the disease, and only in wheelchair bound patients.  In our series, respiratory 
muscle involvement never preceded limb muscle involvement as in many other LGMDs except 
LGMD2I, that can be characterized by early and prominent respiratory involvement (Poppe et al, 
2003; Boito et al, 2005). The age at start of assisted ventilation was independent of phenotype and 
disease duration (median 39 years of age for severe and 41 for mild patients). 
Seventeen different mutations were found distributed over the entire SGCB gene. Three mutations 
were recurrent. The frame-shift mutation c.377_384dup (exon 3) was found in 8 patients coming 
from Northern Italy. Interestingly, the c.377_384dup was previously found to be in linkage 
disequilibrium with neighboring polymorphisms in the population of Northern Italy, suggesting a 
founder effect combined with a relative genetic isolation (Fanin et al, 2000), and our new cases 
add to this conclusion. All the patients carrying the c.377_384dup presented with a severe 
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phenotype that included cardiomyopathy in 3 cases, and all showed a complete absence of the 
four sarcoglycan proteins in skeletal muscle. The c.377_384dup is a truncating mutation, and it has 
been shown that truncated β -SG, missing the extracellular domain, accumulate around the 
nucleus and are not properly localized at the plasma membrane, thus disrupting the sarcoglycan 
complex assembly (Holt et al, 1998). Moreover, β -SG is essential for the formation of the β /d-SG 
core structure, and disruption of this core affects targeting of the sarcoglycan complex to the 
plasma membrane, which explains the complete lack of the complex in muscle biopsies Shi et al, 
2004).   
The c.-22_10dup homozygous mutation was found in five patients presenting a mild phenotype 
and cardiac abnormalities.  All patients presented a variable residual level of sarcoglycans,. This 
mutation encompasses the first ATG codon (start codon) of SGCB gene and it is predicted to be 
frame-shifting with a premature stop codon 22 amino acid downstream. To reconcile the 
discrepancy among a frame-shift mutation, the biochemical data of residual sarcoglycan 
expression in skeletal muscle and the mild phenotype of patients carrying this mutation, we 
hypothesize that the c.-22_10dup alters the Kozak consensus sequence, diminishing the amount 
of protein translated from the first AUG codon and allowing the recognition of the second AUG that 
is predicted to drive the translation of a full length protein. To test this hypothesis, we used the 
DNA TIS Miner and the ATGpr algorithms (http://www.hri.co.jp/atgpr/ATGpr_sim.html) (Nishikawa 
et al, 2000). Both algorithms predicted that, in the mutated sequence, translation would start from 
the second ATG upstream of the annotated SGCB ORF, but with less efficiency compared with the 
reference wild type ATG. Finally, the c.341C>T missense mutation was found in 6 patients. This 
mutation is located few amino acids downstream of the transmembrane domain in the C-terminal 
extracellular domain. The N-terminal half extracellular domain is important for sarcoglycan 
interaction and disruption of the b/d-SG interaction will affect membrane localization (Chen et al, 
2006).  Immunofluorescence analyses in our patients further confirm these findings. Patients 
carrying this mutation present different phenotypes, severe or mild, with or without 
cardiomyopathy. To explain this phenotype variability, we hypothesize that other, unrecognized 
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polymorphisms in the sarcoglycans or other related proteins may further modify the stability of the 
sarcoglycan complex or other still unknown mechanisms.   
As previously described in smaller cohorts of sarcoglycanopathies, the level of protein expression 
in skeletal muscle predicts disease severity (Guglieri et al, 2008). In our cohort a complete 
absence of sarcoglycan complex is common in severe patients, and it was never detected in milder 
patients in whom a variable reduction in one or more sarcoglycans was noted.  Loss of ambulation 
occurred significantly earlier in in patients with observed absence of protein compared to residual 
protein expression. As expected, there was a correlation between the predicted effect of mutations 
on protein sequence, and immunofluorescence/immunoblot results.  All mutations predicted to 
cause a frameshift or a premature termination codon resulted in absent labeling for sarcoglycans, 
and missense mutations showed variable sarcoglycan labeling, from absent to  normal,  reflecting 
different impact of individual aminoacid changes on sarcoglycan assembly.  Sarcoglycan 
expression in muscle is a strong predictor of age at loss of ambulation and may be used as 
prognostic factor in patients stratification for future clinical studies. 
This study demonstrates in a large multicentric cohort that LGMD2E may present a highly variable 
phenotype and that clinical course may vary. We could not identify episodes of rhabdomyolysis in 
LGMD2E patients, however we could observe the presence of frequent muscle pain in active 
patients (75%). This can suggest an increased membrane fragility that in specific cases can lead to 
rhabdomyolysis. We also confirm the high prevalence of cardiac involvement in LGMD2E, 
characterized by structural and rhythm abnormalities that can appear at any stage of the disease, 
indicating that cardiac function should be carefully monitored since early stages of the disease. A 
severe respiratory involvement is less frequent and late-appearing. The knowledge of SGCB gene 
mutations and sarcoglycan protein expression offer a prediction of the severity of the phenotype. 
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AIM4: 
The role of EMG with long exercise test in the diagnosis  
of McArdle disease 
 
RATIONALE 
McArdle disease (Glycogenosis type V, GSDV) is the most frequent metabolic myopathy 
caused by deficiency, usually complete absence, of the glycogenolytic enzyme myophosphorylase, 
due to mutations in the PYGM gene, encoding glycogen phosphorylase, muscle form (McArdle, 
1951; Bruno et al, 2006; Nogales-Gadea et al, 2015).  
GSDV patients present a typical phenotype characterized by juvenile onset of exercise 
intolerance with muscle pain and early fatigue. Patients generally present the pathognomonic 
phenomenon of “second wind”, characterized by enhanced tolerance to aerobic exercise occurring 
within 10 minutes after starting the effort. Beyond the typical exercise intolerance, patients often 
describe severe symptoms during resting periods after abnormal efforts. These include profound 
fatigue and intense muscle pain, persistent muscular contractures, and myoglobinuria with possibly 
acute renal failure due to rhabdomyolysis. A small proportion of patients develop a progressive 
weakness of axial and proximal upper limb muscles in adult age (after the age of 50) (Nadaj-
Pakleza et al, 2009; Vieitez et al, 2011; Lucia et al, 2012). Despite a homogeneous enzymatic 
background, patients can present phenotypes of variable severity (Aquaron et al, 2007). 
 The diagnosis of GSDV, which should be raised in patients with short exercise intolerance 
and high CK levels at rest, relies on the following analysis: non-ischemic forearm exercise test, 
cycling tests, muscle biopsy and gene testing. The non-ischemic forearm exercise test (also known 
as the Grip Test) typically shows no increase in plasma lactate concentration and 
hyperammoniemia (Hogrel et al 2001 and 2015; Kazemi-Esfarjani et al, 2002). The cycling test is 
also a specific, sensitive, and simple test that is based on the pathognomonic heart rate response 
observed in the "second wind" phenomenon (Vissing and Haller, 2003). The muscle biopsy is 
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commonly no longer needed when in vivo metabolic studies are suggestive of McArdle disease as 
PYGM mutations are easily detected by specialized genetic laboratories. 
 The pathogenic mechanisms that underlie the disease are complex and go beyond the only 
glycolytic pathway blockade. The incorrect utilization of glycogen secondarily determines absence 
of lactate production, defective acidification of muscle cells, and limited production of ATP. This 
leads to impairment of membrane pumps function, impaired excitation–contraction coupling and 
post-exercise sarcolemmal inexcitability (Vissing and Haller, 2012).  
 The functional consequences of ion channel abnormalities on muscle membrane 
excitability could be studied by electromyography (EMG) with exercise tests in patients with muscle 
channelopathies (Fournier et al, 2004). Thus, the aim of this study was to determine the role of 
EMG associated with long exercise test (LET) in the diagnosis of GSDV and in the evaluation of 
the secondary biochemical and ionic pump defects of the disease. 
 
METHODS  
Patient selection 
Twenty-five consecutive patients with diagnosis of GSDV (18M, 7F, age 39,2 ±16,3 years) were 
included in the study. The diagnosis was confirmed by molecular analysis of PYGM gene and/or 
assessment of myophosphorylase activity on muscle biopsy. Severity of the disease was graded 
according to the currently used scale (Martinuzzi et al, 2003): 0 = asymptomatic or minimally 
symptomatic (mild exercise intolerance, but no functional limitation in any daily life activity); 1 = 
exercise intolerance, contractures, myalgia, and limitation of acute strenuous exercise, and 
occasionally in daily life activities, without myoglobinuria or muscle wasting and weakness; 2 = 
same as 1, plus recurrent exertional myoglobinuria, moderate restriction in exercise, and limitation 
in daily life activities; 3 = same as 2, with fixed muscle weakness and severe limitations on 
exercise and most daily life activities. 
Two patient groups were selected as controls: a group of 14 healthy subjects and a group 
including 25 consecutive patients (13M, 12F, age 35.9 ±10.5 years) referring to the Neuromuscular 
Center of Paris for metabolic acute rhabdomyolysis (confirmed by CK levels > 5.000 U/L and/or 
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increase >20 times of rest CK levels) in which subsequent diagnostic tests (i.e. grip test, muscle 
biopsy, genetic analyses, etc) excluded the diagnosis of GSDV. Rhabdomyolysis could be relied to 
a molecular diagnosis in only 6 patients: 2 with phosphoglucomutase deficiency (2 mutations in 
PGM1 gene), 3 with very long chain acyl-CoA dehydrogenase (VLCAD) deficiency (ACADVL 
gene) and 1 with long chain acyl-CoA dehydrogenase (LCHAD) deficiency (HADHA gene).  
The study was conducted after obtaining written informed consent from each patient, according to 
the European Union and French bioethics laws, as well as the Convention of Helsinki.  
 
 
EMG Protocol 
Patients and controls were examined using the standardized EMG protocol previously described 
by our group for muscle channelopathies13. The overall duration of the protocol was about 40 
minutes.  
1. Long Exercise Test (LET). The analysis of the compound muscle action potential (CMAP) 
amplitude before and after exercise provides information on changes in the number of active fibers 
and on their ability to depolarize and repolarize. CMAPs were evoked by supramaximal ulnar nerve 
stimulation at the wrist using a bipolar bar electrode, and recorded from right abductor digiti minimi 
(ADM) muscle using skin electrodes. CMAPs were first monitored before exercise every 1–2 
minutes to allow baseline stabilization. The patient was then asked to contract the ADM as strongly 
as possible in isometric conditions for 5 minutes. A bandage around the tested hand prevented 
articulation displacements and facilitated isometric effort during the exercise test. After completion 
of the exercise, the patient was instructed to completely relax while CMAPs were measured at 
regular time intervals after the end of exercise: 2 seconds immediately after cessation of exercise, 
then every minute for 5 minutes, and finally every 5 minutes until 30 minutes.  
Technical precautions include: careful positioning of recording electrodes to ensure maximal 
CMAP amplitude; careful positioning of stimulator electrode in the best position to obtain 
supramaximal activation of the nerve at each time point; brief (2-3 seconds) resting periods during 
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effort, every 45-60 seconds, to prevent ischemia; skin temperature monitoring between 32-34°C; 
frequent absorption of sweat film that can alter the CMAP response.  
2. Nerve conduction studies: motor and sensory nerve conduction velocity of median, ulnar and 
peroneal nerves. 
3. Repetitive Nerve Stimulation (RNS): to tsest neuromuscular transmission (10 stimuli at 3Hz) in 
several nerve-muscle couples (axillary-trapezius, radial-anconeus, peroneal-tibialis anterior). 
4. Needle EMG: to identify myopathic changes such as abnormal spontaneous activity; short, 
small and polyphasic Motor Unit Action Potential, etc. Proximal (trapezius, deltoid, vastus medialis) 
and distal (extensor digiti communis, tibialis anterior) muscles were studied. 
Statistical Analysis 
Descriptive statistics (mean, range, standard deviation, standard error of the mean) were used to 
describe patient’s demographic and clinical characteristics for continuous variables. The Shapiro–
Wilk test was used to check for normality of the data. For normally distributed variables, repeated 
measures analysis of variance was performed. ROC curves were calculated with specific tool 
(Eng, 2014; available at http://www.jrocfit.org).  
RESULTS 
Patient population 
The characteristics, clinical features and results of diagnostics tests of the twenty-five GSDV 
patients included in the study are shown in Table XV. All patients were symptomatic, with different 
degrees of severity: 3 patients were classified in class 1 (exercise intolerance), 14 in class 2 (+ 
rhabdomyolysis) and 8 in class 3 (+ fixed weakness). CK levels were lower than 2x normal values 
in 6/25 patients in at least one evaluation. Grip test showed a typical GSDV pattern with absence 
of lactate production and hyperammoniemia post-exercise in 13/13; two siblings (pt. 24 and 25) 
presented also elevated lactate levels at rest. Muscle biopsy (n = 14) showed in all patients the 
peculiar features, such as glycogen vacuoles and no expression of myophopshorylase. 
 
 
Table XV (next page) GSDV patients: demography, clinical features and diagnostic tools. 
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EMG Protocol 
The standard needle EMG showed non-specific myopathic changes in 5/25 GSDV patients and 
6/25 with rhabdomyolysis. No abnormalities were found in neuromuscular transmission with RNS 
or in short exercise test.  
Changes in CMAP amplitudes along the LET of the three cohorts are shown in Fig. 19. All 
patients and controls had CMAP values within normal values at baseline. The results are thus 
expressed as a percentage of the reference value measured before exercise (CMAP amplitude 
before exercise = 100%). Healthy controls presented a mild drop (-10%) in amplitude immediately 
after effort, rapidly normalized within the first minute. In GSDV patients LET disclosed an abnormal 
post-exercise drop in CMAP amplitude in 23/25 GSDV patients (92%). The decrement usually 
appeared immediately after exercise (average -19% ±15) and reached its maximum (up to -
27%±14) at 20 min, after a transient plateau phase (lasting 5 to 10 min).  No correlations could be 
found between CMAP decrease in LET and age or sex.  
Two GSDV patients (Pt 9 and 15) had normal LET (decrease of CMAP amplitudes <10%). 
Pt.15 (M, 58 yrs) was very sportive in his youth (cycling), and was diagnosed at age 55 yrs 
because of high CK levels. He presented mild exercise intolerance, without rhabdomyolysis 
episodes and PYGM molecular analysis identified a missense mutation (c.1804C>T, p.Arg602Trp) 
in association with the recurrent mutation (c.148C>T, p.Arg50*). Pt 9 (F, 40 yrs) presented a typical 
but GSDV phenotype with late onset and absence of rhabdomyolysis episodes. Muscle biopsy 
morphological analysis showed typical features, but a low residual myophosphorylase activity was 
detected on muscle biopsy (1 U/G, vn 45 - 81), and only one mutation (p.Arg50*) was identified. 
The heterogeneous population of rhabdomyolysis presented minimal changes during LET. 
In detail, 16/25 patients (64%) had normal LET, 5 (24%) a late (>20 min) decrease in CMAP 
amplitudes (up to -29%), 3/25 patients (8%) an immediate and persistent drop (up to -28%) of 
amplitudes and 1/25 an immediate and persistent (+56%) increase of CMAP amplitudes. No 
peculiar patterns were observed in patients with a confirmed molecular diagnosis (LCHAD, 
VLACD, PGM1). 
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supramaximal stimuli at a rate of 18/sec, recording from the abductor digiti minimi muscle by a 
concentric needle electrode. This test produced a considerable (>75%) drop in the amplitude of the 
evoked response over a 100-sec period in affected individuals and could also produce an 
electrically silent 'contracture'. However, subsequent studies did not confirm the specificity of this 
test (Cochrane et al, 1973). This test is no longer performed being unacceptably painful for 
patients and unreliable.  
Other EMG protocols evaluated different characteristics of the effort in McArdle patients. In 
placebo-controlled trials testing creatine in McArdle disease, EMG was used to evaluate muscle 
function during exercise protocols (Vorgerd et al, 2000 and 2002). To this aim, amplitude and 
frequency of EMG signal were recorded from gastrocnemius during 2 minutes of isometric foot 
plantar flexion (30% of maximal voluntary contraction). The EMG study was also studied during 
two cycling tests (an incremental test and a constant workload test) as indicators of motor unit 
recruitment to evaluate the possible contribution of an altered skeletal muscle recruitment strategy 
to the abnormal exercise tolerance of individuals with McArdle disease (Rae et al, 2010). The main 
finding of this study was that McArdle patients required an excessive muscle mass recruitment for 
a given power output and that the state of contractility of their muscles is reduced compared with 
healthy people. However, all these protocols were confined to the research field, did not include 
larger controlled case series and were not applied to diagnostic work-up of myopathic patients. 
 
1. LET is useful in the diagnosis of GSDV 
Our study indicates that Long Exercise Test (LET) can be usefully and easily added in the 
diagnostic process of suspected McArdle disease.  GSDV was chosen to study the role of EMG 
with long exercise test for several reasons. GSDV is the most frequent muscle glycogenosis. The 
vast majority of GSDV patients are biochemically homogeneous, presenting a complete absence 
of enzymatic activity; this determines a complete absence of lactate production that limits the 
variability of the response to LET. GSDV patients’ symptoms are especially evident during exercise 
tasks involving both aerobic and anaerobic glycolysis for muscle ATP production. Two types of 
effort are more likely to cause symptoms: brief intense isometric exercise, such as lifting heavy 
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weights, or less intense but sustained dynamic exercise, such as running or climbing a hill (Di 
Mauro, 2007). In EMG with LET the patients are asked to perform an intense isometric contraction 
of a little muscle (ADM), thus mimicking the first type of effort.  
The LET pattern of GSDV patients was significantly different from controls, characterized 
by a marked drop in CMAP amplitude (-19% on average) appearing immediately after the effort 
(usually within the first minute) and lasting until the end of the 30-min observational period (Fig. 
19). This pattern was observed only in 3 patients referred for rhabdomyolysis (one with 
phosphoglucomutase deficiency and two undiagnosed) and in no healthy controls. Patients 
referring for rhabdomyolysis were chosen as control group because one the main aim of this study 
was to evaluate the role of EMG in the diagnostic process of GSDV, and frequently the first cause 
of medical consultation of GSDV patients is an episode of rhabdomyolysis. This serious event can 
be observed in several genetic and non-genetic diseases, but a definitive molecular diagnosis is 
not frequently achieved despite several diagnostic tests (Scalco et al, 2015).  
In this study, we demonstrated that the LET could differentiate the patients affected by 
GSDV from patients presenting rhabdomyolysis due to other causes. The late-onset decrease of 
CMAP amplitude in our population of patients referred for rhabdomyolysis (p<0.05 compared to 
healthy controls) cannot be deeply understood, because the diseases underlying this event in our 
case series are very heterogeneous and often undetermined. The LET pattern observed in patients 
with GSDV is also different from all the previously published LET patterns for channelopathies; 
these diseases do not enter in the differential diagnosis of GSDV and thus were not included in this 
study.  
Our findings confirm the first report of an EMG exercise test in one patient suffering from 
McArdle disease (Lorenzoni et al, 2005). In this reported patient, a decrease in CMAP amplitude 
was observed after short effort (60-90 sec) in several nerve-muscle couples. However, these 
findings were never confirmed in larger series. Furthermore, the long effort proposed in our study 
is more prone to reproduce clinical symptoms, and the longer observation after the effort let us to 
observe the persistence of the abnormalities and to increase the sensibility of the test.  
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There are actually in use some diagnostic tools that can easily and specifically guide 
toward the diagnosis of GSDV. The grip test is actually the most used and accurate tool in the 
diagnosis of McArdle disease: when performed with standardized procedures it has a sensitivity up 
to 100%, a specificity of 99.7% and a positive predictive value of more than 90% (Hogrel et al, 
2015). Muscle biopsy easily detects specific features (i.e. increase in glycogen content, typical 
subsarcolemmal vacuolar blebs) and can be used to perform specific biochemical and 
histoenzymatic  (no reactivity to myophosphorylase histochemical stain).  
The standard EMG is routinely performed in patients with suspected myopathy or 
hyperCKemia, but has a limited role in the etiologic diagnostic process of a suspected GSDV, 
being able to identify only non-specific myopathic changes in a small proportion of cases (20% in 
our series). In this study, we demonstrated that the LET increases the diagnostic power of EMG in 
the diagnosis of GSDV compared to patients referring for rhabdomyolysis (ROC curves > 0.85 at 
all time points from 1 to 20 min) and normal subjects. This test is less sensitive and specific than 
other diagnostic tools. However, it has favorable characteristics: it is easily performed during a 
standard diagnostic exam and is well tolerated by patients; it is safer than cycling tests, which may 
– rarely – determine rhabdomyolysis; and it is non-invasive, in contrast with muscle biopsy. The 
LET thus nicely complement the grip test, for which the diagnostic power for McArdle has been 
proved to be excellent (Kazemi-Esfarjani et al, 2002; Hogrel et al, 2015). Furthermore, its 
correlation with clinical phenotype and its repeatability indicate LET as a potential outcome 
measure in McArdle disease.  
2. LET correlates with clinical phenotype.  
  Two patients among our cohort of GSDV patients had normal LET. They both presented a 
mild phenotype, and a residual myophosphorylase enzymatic activity was demonstrated in one. It 
has been previously demonstrated that a residual amount of myophosphorylase activity is 
sufficient for allowing a minimal lactate production, and thus to mitigate biochemical secondary 
dysfunction, attenuate muscle symptoms and increase effort abilities (Vissing et al, 2009). The LET 
results that we observed in these two patients further confirm these observations.  
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3. LET as potential outcome measure in McArdle disease. 
No curative treatment is currently available for McArdle disease. Some dietary treatments 
(i.e. sucrose before exercise, carbohydrate-rich diet) and training protocols were demonstrated to 
be effective in alleviating exercise intolerance symptoms (Vissing and Haller, 2003; Ollivier et al, 
2005; Andersen and Vissing, 2008; Andersen et al, 2008, Santalla et al, 2014). However, no large 
controlled studies are available, and outcome measures to evaluate effectiveness are still scarce. 
The 31P Magnetic Resonance Spectroscopy can be used in McArdle disease to measure 
intracellular pH and concentrations of the energy-rich compounds phospho-creatine and ATP 
(Vorgerd et al, 2000). However, this technique requires specialized centers, is time-consuming and 
expensive, and is therefore not an ideal tool neither in the diagnosis of GSDV nor as outcome 
measure in multi-center treatment trials. The outcome measures actually used for McArdle disease 
include exercise cycling test, 12-minute walk test, quality of life and pain or fatigue scales 
(Quinlivan and Vissing, 2007; Quinlivan et al, 2015; Ricci et al, 2015). The cycling test accurately 
measures effort abilities, but it doesn’t take into account all the post-exercise effects of the effort, 
such as pain and fatigue, that prominently affect patients’ daily life (Vissing and Haller, 2003). Few 
quality of life and pain scales study these aspects, but in a qualitative more than quantitative 
manner and from a subjective more than objective perspective (Ollivier et al, 2005). The LET that 
we evaluated in this study can be thus usefully used as potential outcome measure to evaluate 
post-effort dysfunction of GSDV muscles.  
4. Mechanisms of post-exercise symptoms and LET Abnormalities in McArdle disease. 
 The mechanisms underlying the post-exercise abnormalities observed in LET are complex. 
The absence of myophosphorylase completely blocks anaerobic glycolysis, which is fundamental 
in normal muscle function during high-intensity exercise. However, beyond the simple failure of 
energy production for muscle contraction, several pathophysiological mechanisms lead to 
sarcolemmal dysfunction in McArdle disease. 
The failure of lactate production reduces the normal fall of muscle pH. The abnormally high 
pH decreases the creatine kinase reaction (PCr hydrolysis + ADP phosphorylation) that is normally 
stimulated by [H+] production via glycolysis. Consequences of this include the presence of 
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elevated levels of ADP during exercise and inhibition of ATPases, including Na–K ATPase and 
Ca–ATPase. Secondarily, AMP levels are increased (via the adenylate kinase reactions), thus 
accelerating AMP deamination (via myoadenylate deaminase) and increasing ammonia production 
(that is systematically observed during the grip test). Furthermore, several studies in GSDV 
patients demonstrated loss of osmotic effect related to lactate accumulation. The absence of 
increase of water content in exercised muscle is cause of the exaggerated rise in blood and 
presumably extracellular potassium, that contributes to sarcolemmal inexcitability and impaired 
Na–K pump function. Finally, a deficient substrate-level phosphorylation of ADP such as blocked 
ATP production in anaerobic glycolysis was observed, that preferentially supply ATP for the 
membrane sodium–potassium ATPase. This further contributes to impairment of membrane pump 
function and finally to the abnormal post-effort fatigue and sarcolemmal failure (Gruener et al, 
1968; Brandt et al, 1977; Haller et al, 1998; Fauler et al, 2012; Vissing and Haller, 2012; Ørngreen 
et al, 2015; Nogales-Gadea et al, 2016). All these secondary cellular events in GSDV are strongly 
related to the post-effort symptoms, such as intense and prolonged fatigue, persistent muscular 
pain and increase in muscle volumes leading to acute rhabdomyolysis. These symptoms are often 
underestimated by physicians and researchers, actively studying exercise capacity of GSDV 
patients, but have a major impact on quality of daily life of GSDV patients. The post-exercise 
sarcolemmal inexcitability observed on LET in GSDV explore and confirm these complex 
biochemical mechanisms determined by the absence of myophosphorylase activity, beyond the 
simple glycolytic blockade. 
In conclusion, in our study we demonstrated that LET can guide clinicians toward the diagnosis of 
GSDV, being a highly sensitive and specific test, that can be easily performed in an outpatient 
setting and well tolerated by patients. It correlates well with GSDV phenotype, and with the very 
disabling post-effort symptoms, thus can be studied as a potential outcome measure. Thus, LET is 
an important in vivo study of muscle functioning not only in “primary” muscle channelopathies but 
also in metabolic myopathies that secondarily affect ionic pumps.  
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Aim 5 
Construction of a Gene Panel for Rhabdomyolysis 
 
 
In recent years, the evolution of molecular techniques allowed to develop new more efficient 
methods (NGS, Next Generation Sequencing) for the analysis of exomes ("whole exome 
sequencing") or of multiple genes involved in specific diseases ("gene panels"). These promising 
techniques are more and more used especially in rare genetic diseases, for example in LGMDs 
and in mitochondrial diseases. More recently a specific panel for rhabdomyolysis has been 
proposed by Olpin et al (2015) and is currently under evaluation in England.  
Generally, NGS allows an increased mutation detection rate, a reduction of time and cost, and 
identification of mutations in several genes not previously associated with muscle disorders. On 
the other hand, NGS still has several limitations: the analysis of the large generated amount of 
data (output) requires specialized centres and it is time consuming; the pathogenicity of several 
genetic variants is doubtful; NGS output are difficult to be analysed in single patients (and this is 
frequently the case in rhabdomyolysis). The good selection of candidate genes to be studied in a 
panel and the correct identification and characterization of good patients candidate for “gene 
panels” are mandatory for best results.  
Medline search including “rhabdomyolysis”, “myoglobinuria”, “metabolic myopathy” was done and 
14,686 articles were identified (8,329 rhabdomyolysis, 2,108 myoglobinuria and 4, 249 metabolic 
myopathy).  The articles were screened and all genes reported to be associated with 
rhabomyolysis were selected. 
The screening led us to propose a “rhabdomyolysis panel” that includes 32 genes that are mutated 
in diseases known to manifest with rhabdomyolysis and genes that participate in the mechanisms 
known to be disrupted in rhabdomyolysis (See Table XVI). These genes are involved in: i) 
glycogen metabolism; ii) lipid metabolism; iii) calcium homeostasis; iv) others (lipin, ISCU).  Beside 
ISCU no other genes involved in mitochondrial myopathies or genes involved in LGMDs were 
included since specific panels are already available and in use (Mitocapture and LGMDs).
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Due to the rapid evolution of knowledge in these rare diseases, and the increasing number of new 
genes that are being discovered, a cost - benefit analysis suggests that selected patients should 
be studied with the sequencing of all the exome (WES), followed by subsequent analysis only of 
the genes pre-selected in the panel. In fact, the slightly higher cost of WES compared to the 
sequencing of panel genes would be offset by the possibility of studying other genes without 
further sequencing analysis, if the first-step analysis resulted negative. On the other hand, it is not 
feasible to propose a complete WES (sequencing and analysis of all exomes) for all patients with 
rhabdomyolysis, because it is time consuming and expensive, it would be difficult to distinguish 
pathogenic mutations from the numerous variants identified (especially if parents are not included 
in the WES), and it would increase the ethical issues of the analysis (i.e. for accidental discovery of 
pathogenic mutations non-related to rhabdomyolysis).  
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CONCLUSIONS 
The main objective of this study was the amelioration of the diagnostic process for patients with 
suspected myopathy manifesting with rhabdomyolysis.  
The first step was the identification of the current diagnostic work up in rhabdomyolysis and 
estimate of the diagnostic yield.  
We analyzed the clinical features and diagnostic procedures performed in patients with 
rhabdomyolysis (aim1) in a retrospective study including all consecutive patients (n = 208) referred 
for rhabdomyolysis to a Reference Centre for Neuromuscular Diseases. We verified that the final 
diagnosis could not be identified in 118 patients (57%), despite an extensive work up. A genetic 
disease was observed in 19,7% and a non-genetic cause was found in 23,6%. Some diagnostic 
tests were confirmed to have high specificity and/or sensitivity for specific diseases, such as: grip 
tests in the diagnosis of McArdle's disease and in phosphoglucomutase 1 deficit; profile of 
acylcarnitines in VLCAD and CPT2 deficiency; muscle biopsy in McArdle's disease and in some 
muscular dystrophies. Overall, however, the diagnostic tools used in the last 16 years were 
insufficient in guiding the diagnostic process to a defined etiologic diagnosis. We also identified few 
cases presenting rhabdomyolyses due to rare diseases (i.e. DNA2 mutations), or presenting rare 
causes of rhabdomyolysis rare (i.e. myeloma; hyperthyroidism; dermatomyosytis) or previously 
unknown (i.e. Myotonic Dystrophy Type 2). The clinical features of the episode of rhabdomyolysis 
(i.e. trigger, max CK, symptoms, etc.) could not guide toward a specific diagnosis, and most of the 
cases remained unsolved despite the long and costly workup.     
In the second aim of the study (aim 2) we identified and characterized a new genetic cause of 
rhabdomyolysis, the CASQ1 – related myopathy. This disease has been recently discovered in 
Italian patients affected by mild myopathy, all carrying the same mutation (p.Asp244Gly ) because 
of a founder effect. In the present study, we collected data concerning 17 patients, and we widened 
the clinical spectrum, including rhabdomyolysis and severe course in older patients, expanded the 
CASQ1 mutational spectrum by identifying a novel mutation. We provided information about the 
clinical features, muscle imaging and histopathology that can orient towards the diagnosis of 
CASQ1-related myopathy. 
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In the third aim we investigated the prevalence of rhabdomyolyses in a large population of beta-
sarcoglycanopathy patients.  In a multicentric International study we collected natural history data 
of 32 LGMD2E patients with different disease severity. We did not detect any case of overt 
rhabdomyolysis; however, we confirmed the high prevalence of muscle pain in active patients, 
suggesting the presence of membrane fragility exacerbated by muscle activity. We described 
disease evolution, and correlations between genotype, protein expression, and phenotype. 
The fourth objective (aim 4) focused on diagnostic tools to be used in cases of rhabdomyolysis, 
and in particular on the role of EMG with provocative test: the Long Exercise Test (LET) for the 
diagnosis of McArdle disease (GSDV).  LET differentiate GSDV patients from patients referred for 
rhabdomyolysis from other causes and healthy subjects. LET showed a marked and immediate 
reduction of compound action potential (CMAP) amplitude after effort, correlated to membrane 
inexcitability that occurs after exertion in GSDV patients. We also demonstrated that LET can also 
be used as an outcome measure, because it is related to the severity of symptoms and is 
consistent with post-exercise symptoms reported by patients.  
Finally, we proposed a rhabdomyolysis gene panel to be used in undiagnosed patients. This panel 
includes genes involved in glycogen, lipid metabolism and in calcium homeostasis. 
 
Proposal of a diagnostic work-up for rhabdomyolysis 
Few diagnostic flow charts for rhabdomyolysis have been published in recent years: these are 
certainly helpful, but they are based more on theoretical basis and expertise of neuromuscular 
specialists than on clinical data obtained from large case series. In fact, no population studies have 
been performed so far in myopathies manifesting with rhabdomyolysis.  
The flow chart proposed by  Zutt et al (2014) is shown in Figure 21. This elegant and complete 
protocol has some limitations that need to be underlined. First, the authors propose to stop 
investigations after blood tests in patients presenting a single episode of rhabdomyolysis, if no 
positive family history or myalgias/cramps are present. This should be avoided, because of the 
unknown risk of recurrence, the high impact of rhabdomyolysis on quality of daily life of patients, 
and the potential costs of the intensive medical care needed in acute episodes. In the present 
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study, we report several patients without any past medical history or family history that after a 
single episode were diagnosed with a genetic disease (frequently RYR1 mutations) and, more 
importantly, with potentially treatable disorders disclosed by rhabdomyolysis (i.e. myeloma, 
dermatomyositis, etc.).  Few additional exams are therefore needed even after a single episode of 
rhabdomyolysis.  Muscle biopsy is correctly proposed as a second line exam after non-ischemic 
grip test and acylcarnitines studies, and we agree that it remains an important tool to be performed 
in case of rhabdomyolysis. However, in our study we showed that only few histopathological 
features could certainly guide toward specific diagnoses, because more often muscle biopsy 
shows unspecific myopathic features. Furthermore, biochemical assays on muscle tissue or blood 
cells seem less useful in guiding toward specific diagnosis. The high cost (in money and time), the 
low number of specialized laboratories available, the numerous technical precautions and 
limitations (i.e. difficulties in sample collection, transportation and conservation, etc.) and their low 
sensitivity limit their use for diagnostic purposes. They remain very useful, for example, for the 
confirmation of doubtful genetic defects. 
 
Fig. 21. Diagnostic flow-chart 
proposed by Zutt et al, 2014. 
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Fig. 22. Diagnostic flow-chart proposed by Nance and Mammen (2015). 
 
The protocol proposed by Nance and Mammen (2015) is shown in Fig. 22. This very elegant 
protocol underlines the importance of excluding acquired causes of rhabdomyolysis as a first step, 
and the importance of an accurate evaluation of general clinical features (step 2). Unfortunately, in 
our study we demonstrated that rarely the features of the episodes, the relationship between effort 
and symptoms onset and the concomitant clinical clues are helpful to direct genetic tests. The 
authors include the most recent scientific and technical advances such as NGS (step 3), and in 
step 4 suggest that the diagnosis of “Benign Rhabdomyolysis” is a diagnosis of exclusion, that can 
be posed in exertional rhabdomyolysis only after that several diagnostic tools have been performed 
and resulted negative. It is to note, however, that due to the potential severity of the episode of 
exertional rhabdomyolyses and the unknown risk of recurrence, the term “benign” seems 
misleading.   
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Fig. 23. Diagnostic flow-chart proposed by Olpin et al (2015). 
 
 
The flow chart proposed by Olpin et al (2015) (Fig. 23) is centered on the importance of a specific 
gene panel for rhabdomyolysis. The authors suggest to proceede directly to the Gene Panel after 
few basic investigations (blood tests and possibly limited exercise testing) and the exclusion of 
GSDV or mitochondrial disease by clinical evaluation. Neuromuscular specialists and deeper 
investigations are envisaged only if no clear diagnosis is acquired from NGS. With this approach, 
several non-genetic rhabdomyolyses and rare diseases would be studied with NGS, with a high 
cost and scarce results.    
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Here we suggest a new diagnostic algorithm, shown in Fig. 24, that integrates the actual 
knowledge on metabolic myopathies and rhabdomyolysis with the results of the present study. 
The first step includes an accurate medical history, clinical evaluation, and family history to 
delineate the scenario in which rhabdomyolysis occurred and, rarely, suggest specific diagnoses. 
If an evident external cause is excluded (i.e. trauma, epilepsy, etc.), few selected first line exams, 
that include blood exams, acylcarnitines, grip test and EMG, need to be performed: 
i) To guide toward the diagnosis of the most frequent or peculiar causes of rhabdomyolysis: 
GSDV diagnosis with Grip Test (eventually EMG with Long Exercise Test); CPT2 and 
LCHAD with the typical profile of acylcarnitines; etc. 
ii) To disclose some of the non-genetic causes of rhabdomyolysis that can be potentially 
treatable and cannot be distinguished from genetic diseases: endocrine disease 
(thyroid), myeloma (profile of blood proteins); inflammatory myopathies; etc. 
iii) To screen for treatable muscle disorders with low-costs tests: GSDII with enzymatic dosage 
in Dried Blood Spot. 
iv) To identify signs of diseases in which gene panels are scarcely sensitive (i.e. myotonic 
discharges on EMG in DM1 and DM2) 
v) To identify signs that can suggest specific diagnosis: hemolytic anemia in PGK; peripheral 
neuropathy in LCHAD; etc. 
The muscle biopsy should be performed as a second step in all non-diagnosed patients. Muscle 
tissue analysis should include at least: 
i) Standard histopathological stains (to evaluate muscle structure, glycogen and lipid content, 
mitochondrial features, inflammatory elements, etc.);  
ii) Myophosphorylase stain;  
iii) Western-blot (WB) and/or immunohistochemistry (IHC) for sarcolemmal proteins.  
If no peculiar patterns can be evident on muscle tissue, the analysis of cDNA for RYR1 gene 
should be performed. This analysis is preferred to the DNA analysis extracted from blood cells, 
because it is easier, quicker and more reliable for this large gene in which several variations are 
usually identified.  
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The “pure exertional rhabdomyolysis" remains a diagnosis of exclusion that can be carefully posed 
in non-myopathic patients when: i) the episode is triggered by effort in favoring conditions, ii) no 
major abnormalities are observed on diagnostic tools, iii) family history is negative for 
rhabdomyolysis, high CK or intense myalgias; iv) no RYR1 variations are detected. It is to note, 
however, that in patients with “pure exertional rhabdomyolysis” it is not possible to exclude rare 
diseases, milder mutations in pathogenic genes or genetic variations that affect the physiological 
response to exercise. Therefore, the risk of recurrence and complications should not be completely 
excluded.  
For the non-diagnosed patients, the combination of medical history, laboratory findings and 
histopathological features should guide toward NGS, without any further biochemical or functional 
test. We propose three main gene panels that are under study (“rhabdomyolysis panel”, see Aim 5) 
or already available for diagnostic purposes (“mitochondrial disorders” and “Limb-Girdle Muscular 
Dystrophies”). 
Patients presenting clinical features suggestive for mitochondrial disorders (i.e. short stature, 
ptosis, deafness, etc.), increased levels of lactate, peripheral neuropathy on EMG and/or 
mitochondrial abnormalities on muscle biopsy should be preliminary studied with a specific panel 
for mitochondrial diseases. The one in use in France, for example, includes 101 nuclear genes and 
all the mitochondrial DNA (37 genes) associated with diseases or involved in mitochondrial 
functioning (Mitocapture). Patients presenting very high CK levels, myopathic changes on EMG, 
and most importantly histopathological features suggesting muscular dystrophy and normal 
sarcolemmal proteins on IHC/WB, should be first studied with the specific panel for LGMDs 
(patients presenting abnormal IHC/WB for sarcolemmal proteins will be first screened by a 
candidate gene approach). All other patients should be studied with the “rhabdomyolysis panel”.  
 
In conclusion, the diagnostic algorithm that we propose will allow cost reduction and time 
optimization, and hopefully will increase the rate of etiological diagnosis of rhabdomyolysis, a 
serious event with major impact on patients' lives that, to date, remains poorly diagnosed. 
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